Hypoxia: The Force that Drives Chronic Kidney Disease

  • Clinical Medicine & Research
  • March 2016,
  • 14
  • (1)
  • 15-
  • 39;
  • DOI: https://doi.org/10.3121/cmr.2015.1282
PDF

Abstract

In the United States the prevalence of end-stage renal disease (ESRD) reached epidemic proportions in 2012 with over 600,000 patients being treated. The rates of ESRD among the elderly are disproportionally high. Consequently, as life expectancy increases and the baby-boom generation reaches retirement age, the already heavy burden imposed by ESRD on the US health care system is set to increase dramatically. ESRD represents the terminal stage of chronic kidney disease (CKD). A large body of evidence indicating that CKD is driven by renal tissue hypoxia has led to the development of therapeutic strategies that increase kidney oxygenation and the contention that chronic hypoxia is the final common pathway to end-stage renal failure. Numerous studies have demonstrated that one of the most potent means by which hypoxic conditions within the kidney produce CKD is by inducing a sustained inflammatory attack by infiltrating leukocytes. Indispensable to this attack is the acquisition by leukocytes of an adhesive phenotype. It was thought that this process resulted exclusively from leukocytes responding to cytokines released from ischemic renal endothelium. However, recently it has been demonstrated that leukocytes also become activated independent of the hypoxic response of endothelial cells. It was found that this endothelium-independent mechanism involves leukocytes directly sensing hypoxia and responding by transcriptional induction of the genes that encode the β2-integrin family of adhesion molecules. This induction likely maintains the long-term inflammation by which hypoxia drives the pathogenesis of CKD. Consequently, targeting these transcriptional mechanisms would appear to represent a promising new therapeutic strategy.

Since the beginning of renal replacement therapy for end stage renal disease (ESRD) through dialysis or transplantation, the number of patients treated for terminal kidney failure worldwide has continued to grow at an annual rate of approximately 7%.1–3 This is far in excess of the annual 1% growth rate of the world population in general. In 2012, a survey of 7 billion people spanning over 230 countries was undertaken.1 This survey found that 3,010,000 patients were being treated for ESRD. Of these, 652,000 were living with a donor organ, and 2,358,000 were on dialysis treatment.

In 2011, the United States spent over 49 billion dollars treating nearly eleven times more ESRD patients than in 1980.4 This trend shows no sign of slowing down.4 In 2003, the prevalence of chronic kidney disease (CKD) in the US adult population was 11% (19.2 million). Of these patients, an estimated 5.9 million individuals had stage 1; 5.3 million had stage 2; 7.6 million had stage 3; 400,000 individuals had stage 4; and 300,000 individuals had stage 5, or kidney failure.5

The incidence of ESRD has already reached epidemic proportions in the United States. Furthermore, the rates of ESRD among the elderly are disproportionably high. Consequently, as life expectancy increases and baby-boomers retire, the already heavy burden imposed by ESRD on the US health care system is predicted to increase dramatically.

The main cause of ESRD is CKD. This in turn is driven by a constellation of interlinked risk factors. Primary amongst these factors are anemia,6–9 diabetic hyperglycemia,10–12 hypertension,13–17 hypercholesterolemia,18–20 cigarette smoking,21–27 air pollution,28–42 atherosclerosis,43–52 repeated episodes of acute kidney injury,53–70 and sleep apnea.71–87 All the risk factors associated with CKD produce inappropriately low oxygen tensions within the kidney. On the basis of this association, Fine et al88 proposed in 2000 that chronic hypoxia is the final common pathway that leads to the development of end-stage renal failure. Subsequently, this theory has been validated by numerous studies.89–99 Particularly informative have been recent experiments where kidney oxygen tension has been reduced with dinitrophenol without affecting markers of oxidative stress. Under these circumstances urinary protein excretion, inflammatory cell infiltration into the kidney, and renal epithelial-to-mesenchymal transition were all increased.100,101 Consequently, there appears to be a direct link between hypoxia and the progression of CKD.

Causes of Kidney Hypoxia

In relation to their weight, the kidneys are the best-perfused organs of the body.102 Paradoxically, however, oxygenation of the renal parenchyma is poor, with oxygen tensions in the renal cortex averaging 30 mm Hg and those in the renal medulla being below 10 mm Hg.103,104 The reason for this dramatic contrast between oxygen supply and oxygenation is due both to the way the kidney is built and to the function it performs. With regard to kidney structure, arterial and venous pre-glomerular and post-glomerular vessels run strictly parallel and in close contact to one another over long distances. This parallel architecture drives the diffusion of oxygen from arterioles to the post-capillary venous system before it can enter the capillary bed.104,105 Compounding the problem of oxygen delivery is that the rate of regional blood inflow to the inner and outer medulla is lower than that to the renal cortex.106 Furthermore, the acute angle between the interlobular artery and the afferent arterioles supplying juxtamedullary glomeruli causes the capillary hematocrit in the medulla to be dramatically lower than that in the cortex. This is due to a phenomenon termed plasma skimming, in which erythrocytes that are primarily in the center of vessels continue to flow in the interlobular artery towards the superficial cortex, while the plasma in the periphery of the capillary is captured by the juxtamedullary afferent arterioles and ultimately flows into vasa recta.107,108 In addition to the architecture of the kidney limiting oxygenation, kidney tubules are characterized by a limited ability to generate energy under anaerobic conditions, causing oxygen to be consumed rapidly in the metabolic processes involved in active salt reabsorption. Consequently, the twin constrains of low oxygen supply dictated by renal structure and high oxygen demand dictated by renal function conspire to make the kidney particularly vulnerable to physiologic and environmental stresses that cause ischemia.

Anemia

Anemia has long been known to be an independent physiologic risk factor for the development of CKD.6–9 The obvious way in which anemia impacts unfavorably on renal oxygenation is that it is characterized by fewer erythrocytes in the circulation and consequently blood with a reduced oxygen-carrying capacity. The Epo-TAgh transgenic mouse has severe anemia caused by targeted disruption of the gene encoding erythropoietin (EPO).109 Consistent with the connection of anemia to the development of CKD, the Epo-TAgh mouse mimics CKD pathology by exhibiting renal hypoxia.9,109 In addition, EPO administration has been shown not only to correct anemia but also protect against ischemia-induced kidney damage.110–112 This protective effect could clearly stem from enhanced delivery of oxygen by an increased mass of erythrocytes. However, the renoprotective ability of EPO also appears to be due to mechanisms independent of its ability to increase red blood cell production.113,114 Here EPO binds a heterodimer on the surface of renal cells composed of the EPO receptor and CD131.115 This binding then elicits a cascade of intracellular signaling events involving the dephosphorylation of p38 mitogen-activated protein kinase and the phosphorylation of Janus kinase 2, signal transducer and activator of transcription 5, serine/threonine protein kinase B, serum and glucocorticoid-regulated kinase 1 and glycogen synthase kinase 3β.113,114,116,117 The net result of these events is that apoptosis is inhibited through reduced expression of pro-apoptopic nuclear factor-κB and Bcl-2-like protein 4 and increased expression of the anti-apoptopic molecules B-cell lymphoma 2, B-cell lymphoma extra-large and X-linked inhibitor of apoptosis protein.113,114,118–122 In addition, EPO effects renoprotection by ameliorating oxidative stress through increased expression of glutathione peroxidase, superoxide dismutase and endothelial nitric oxide synthase.113,123 EPO also down-regulates the ability of renal tissue to produce increased levels of intercellular adhesion molecule 1 and proinflammatory cytokines and chemokines in response to ischemia. As a consequence, renal tissue is less susceptible to attack by neutrophils and macrophages.121,122

Hyperglycemia

Diabetic patients with poorly controlled blood glucose levels are at high risk of developing renal dysfunction, and diabetes-induced renal complications are a major cause of morbidity and mortality.124,125 Diabetes is associated with decreased renal oxygen tension.11 Several mechanisms have been implicated in driving this process. Hyperglycemia induces the formation of reactive oxygen species by renal mitochondria, nicotinamide adenine dinucleotide phosphate oxidase, and uncoupled nitric oxide synthase.10 The reactive oxygen species superoxide then directly interacts with nitric oxide, forming peroxynitrite and, thus, reducing nitric oxide bioavailability. A process independent of reactive oxygen species decreases L-arginine, further reducing the bioavailability of nitric oxide.11 Reduced nitric oxide and increased reactive oxygen species independently both lead to increased oxygen consumption.11 In addition, reduced nitric oxide causes vasoconstriction that limits renal blood perfusion and, therefore, oxygen delivery.12 Hyperglycemia also limits renal perfusion by narrowing the diameter of arterioles within the glomerulus through inducing extracellular collagen accumulation and the proliferation of mesangial, distal tubular epithelial, and vascular smooth muscle cells.126–129 The molecular mechanism by which this is achieved involves hyperglycemia producing sustained activation of protein kinase C and nuclear factor kappa-light-chain-enhancer of activated B cells that in turn stimulates the release of osteopontin.129–134 This growth factor then binds and activates its β3-integrin receptor that signals to induce the synthesis of both DNA and collagen.129,135 An additional consequence of hyperglycemia inducing protein kinase C is that this increases expression of intercellular adhesion molecule 1 by mesangial cells, thus promoting glomerular damage effected by infiltrating mononuclear cells.133 The link between hyperglycemia, renal hypoxia, and the development of CKD is further evidenced by analysis of the obese db/db mouse model of diabetic nephropathy.136 This model exhibits hyperglycemia, increased production of reactive oxygen species, loss of capillaries, arteriolar constriction, and a decrease in resting and maximum blood flow.136–139 Consistent with these characteristics causing kidney damage through hypoxia, the db/db mouse shows increased glomerular expression of hypoxia-inducible factor 1 (HIF-1) and other genes involved in oxidative stress.140

Hypertension

The hallmark of systemic hypertension is chronic induction of multiple vasoconstrictors including the renin-angiotensin-aldosterone system, constrictor prostaglandins and endothelin.141–143 Constriction of blood vessels limits blood flow and consequently reduces oxygen delivery to the kidney.14–17 In addition, hypertension leads the kidney to consume approximately twice as much oxygen as normal to transport a given amount of sodium.16 Consequently, the combination of reduced oxygen delivery caused by vasoconstriction and increased oxygen demand caused by aberrant metabolism results in lower renal oxygenation. Specifically, the oxygen tension of the kidney cortex and medulla has been shown to be approximately 10 mm Hg lower than normal in spontaneously hypertensive rats and other models of hypertension as well as in hypertensive patients.15,89,144–146 The role of hypertension in the progression of CKD was first described in 1914 by Volhard and Fahr.13 Subsequently, it was appreciated that hypertension predisposes to kidney failure by inducing renal hypoxia.147,148 The detrimental effects of hypoxia are exacerbated by hypertension also inducing kidney tissue to generate elevated levels of reactive oxygen species such as superoxide, hydrogen peroxide, peroxynitrite, and hydroxyl radicals.149 These species are formed by elevated intrarenal angiotensin II binding type 1 angiotensin II receptors that then transduce signals to activate the pro-oxidant enzyme nicotinamide adenine dinucleotide phosphate-oxidase.150,151 The generation of reactive oxygen species is further augmented by decreased expression of the anti-oxidant enzymes superoxide dismutase 1 and 3 and isoforms of nitric oxide synthase.151 The reactive oxygen produced as a consequence of hypertension acts in the same way as that generated during hyperglycemia to drive renal hypoxia. That renal hypoxia caused by hypertension directly contributes to the development of CKD is demonstrated by angiotensin receptor blockers, angiotensin-converting enzymes, and the anti-oxidant tempol all normalizing renal oxygenation and function in hypertensive rats.15, 16, 148, 152–154

Hypercholesterolemia

High cholesterol levels have been shown to correlate with reduced renal oxygenation and increased kidney damage in response to ischemia.155–157 One mechanism by which cholesterol likely drives these processes is through its role in determining the physical properties of the cell surface. Cholesterol constitutes the non-polar, hydrophobic lipid of the enveloping layer of the erythrocyte membrane. This cholesterol is in equilibrium with the concentration of plasma cholesterol. Consequently, as the concentration of plasma cholesterol increases so does the cholesterol content of the erythrocyte membrane. Under such circumstances the fluidity of the membrane decreases and the lipid shell stiffens. This produces a greater barrier to oxygen diffusion that both delays oxygen entry into the erythrocyte during saturation and delays oxygen release during desaturation.18–20 Indeed, the percentage change in blood oxygen diffusion has been found to be inversely proportional to plasma cholesterol concentration.18 Consequently, cholesterol contributes to renal hypoxia by reducing the erythrocyte capacity to both load and release oxygen. Hypercholesterolemia also results in lipid deposition in kidney tissue.158 Thus, oxygen delivery by diffusion is again compromised. Furthermore, lipid deposition in renal arteries increases their stiffness and reduces their ability to dilate and deliver an augmented blood flow when oxygen tensions are low.159,160 Besides contributing to renal hypoxia through its physical properties, cholesterol also likely contributes through its metabolism. Resistance to hypoxia-induced kidney damage has been shown to be mediated by increased de novo synthesis of esterified cholesterol and the cholesterol transport protein 18 KDa translocator protein.161–163 However, chronically high cholesterol levels repress expression of both these molecules, so compromising cytoprotection during ischemia.164–167

Cigarette Smoking

Both active and passive cigarette smoking have been found to be independent risk factors for the de novo development of CKD in healthy subjects.168–176 Cigarette smoking is also a major risk factor for the initial development or worsening of preexisting CKD in patients with human immunodeficiency virus infection, chronic obstructive pulmonary disease, diabetes, diabetic nephropathy, hypertension, autosomal polycystic kidney disease, primary glomerulopathies, lupus nephritis, and those who are obese or who have undergone a lung transplant.177–187 In addition, smoking by either the donor or recipient has been shown to adversely influence the function and survival of transplanted kidneys and overall patient survival.170,171,188,189 Allograft survival and function both worsen with increasing pack-years smoked. The number of cigarettes smoked correlates directly with the severity of renal dysfunction and the likelihood that either CKD will develop or a kidney allograft will fail.24,168,170,181,190 Conversely, smoking cessation reduces the risk of developing CKD and is of benefit to patients where the condition pre-exists.176,190,191 Mainstream cigarette smoke has been said to contain 4,000 or more constituents.22–24,192 Some of these, like cadmium and lead, are directly nephrotoxic.193,194 Other constituents like tar, carbon monoxide, nicotine, and reactive oxygen species, effect kidney damage by compromising oxygenation. The accumulation of tar in the lung results in a physical barrier that impairs gas exchange within alveoli. Consequently, carbon dioxide is less effectively released and oxygen less effectively acquired by erythrocytes. In addition, tar further reduces oxygen availability to erythrocytes by inducing inflammatory reactions that demand increased oxygen consumption.22 The carbon monoxide in cigarette smoke reversibly binds various heme-containing proteins within the body. These proteins include hemoglobin, myoglobin, cytochrome P450, and cytochrome oxidase that are responsible for oxygen transport. Since the bond formed between heme and carbon monoxide is less dissociable than the hemeoxygen bond, severe disruption of normal oxygen transport can occur.26,27 The nicotine of cigarette smoke induces degradation of nitric oxide and stimulates parasympathetic nerves. Both these processes constrict the vasculature, so limiting blood flow and oxygen delivery to the kidney.21,25 In addition, nicotine binds a range of nicotinic acetylcholine receptors expressed by mesangial, endothelial, vascular smooth muscle, and renal proximal and distal tubule cells.195–198 These receptors are expressed under normoxic conditions but are induced by both transient and chronic hypoxia.199,200 Upon nicotine binding, receptors mediate activation of protein kinase C that in turn activates nicotinamide adenine dinucleotide phosphate-oxidase to produce reactive oxygen species.195,196,201–204 Stable compounds within cigarette smoke, such as acrolein, also induce endothelial production of reactive oxygen species through activation of nicotinamide adenine dinucleotide phosphate-oxidase.205 These oxygen species then act in the same way as those generated through hypertension and hyperglycemia to drive renal hypoxia and kidney damage. In addition, the reactive oxygen species produced in response to nicotine also induces mesangial cell proliferation and extracellular matrix deposition through pathways that involve increased expression of cyclooxygenase 2-derived prostaglandins and increased phosphorylation of extracellular signal-regulated protein kinases 1 and 2, c-Jun N-terminal kinases, activator protein 1, and protein kinase B.195,196,204,206–210 This aberrant proliferation and deposition mirrors the protein kinase C dependent processes by which hyperglycemia constricts glomerular arterioles to limit blood flow and, hence, oxygen delivery to the kidney. In an additional mirror of hyperglycemia, nicotine also promotes hypoxia by facilitating oxygen-consuming inflammation. This occurs through increased expression of unphosphorylated signal transducer and activator of transcription 3 that induces renal proximal tubule cells to secrete the pro-inflammatory cytokine transforming growth factor β1 and the pro-inflammatory chemokine monocyte chemotactic protein 1.210 Finally, with a higher daily number of cigarettes smoked or a longer duration of smoking the risk of developing hypertension increases.211–213 Consequently, it is logical to assume that beyond its own specific mechanisms of inducing hypoxia-mediated CDK, cigarette smoking also utilizes those manifest in hypertension.

Air Pollution

The ready access of the lungs and blood stream makes them unusually susceptible to the deleterious effects of airborne pollutants.28,29 Carbon monoxide breathed passively from second-hand smoke or atmospheric pollution can produce hypoxic affects similar to those produced by active cigarette smoking.27 Nitrogen dioxide and sulphur dioxide may render hemoglobin useless for oxygen transport by driving its conversion to methemoglobin or sulfhemoglobin.29 Lead and arsine can damage the erythrocyte membrane resulting in anemia.29 Ozone is formed for the most part by the interaction between solar radiation and nitric oxides, carbon monoxide, and volatile hydrocarbons. These are the primary pollutants of traffic exhaust fumes. Ozone causes acute arterial vasoconstriction, reducing blood flow and limiting oxygen delivery.30 Ultrafine particles of aerodynamic diameter 0.1μM are emitted by diesel engines and can pass directly into the blood circulation, limiting oxygen delivery by inducing vasoconstriction, vascular inflammation, and increasing blood viscosity.30–32 Fine particles of 2.5 μM emitted by diesels accumulate within the pulmonary alveoli and cause an inflammatory reaction of the lung that is related both to their physical parameters and the oxidative stress generated by the organic and metallic compounds adsorbed onto their surface.33 These compounds trigger the local production by macrophages and activated alveolar cells of inflammatory cytokines such as interleukin 6 and tumor necrosis factor α and the potent vasoconstrictor endothelin 1.30,32,33 As with diesel particles and cigarette tar, the dust produced from coal, silica, wheat, flax, and rice and the fibers originating from cotton, silk, fiberglass, and asbestos can build up in the lungs, limiting gas exchange and inducing oxygen-consuming inflammation.34–40 Furthermore, dusts originating from agricultural products such as flax, cotton, rice, wheat, and wood are loaded with gram-negative bacterial endotoxin. Exposure to such endotoxin elicits chronic inflammation within the lungs that drives a long-term decline in their function.36–40 In summary, air pollution can reduce renal oxygenation through a host of mechanisms. These include the induction of oxygen-consuming inflammation, that reduces the ability of the lungs to effect gas exchange, and anemia, vasoconstriction, and hemoglobin conversion that reduces the oxygen delivery capacity of the blood stream. That air pollution does indeed compromise kidney function is supported by the finding that glomerular filtration is compromised by breathing heavy metals from copper smelters and by living in close proximity to major roadways.41,42 In addition, rats exposed to either the asbestos group member amosite or to passive smoking develop significant glomerulosclerosis and tubulinterstitial fibrosis, and occupational exposure to silica, fiberglass, or solvents has been linked to an increased risk of developing ESRD.35,214

Atherosclerosis

Approximately six million Americans have combined atherosclerosis and kidney disease.47 The development of atherosclerosis stems from multiple interactions among injurious stimuli and the healing or reparative responses of the arterial wall.48 After endothelial injury, direct cell-cell interaction and the secretion of chemotactic and growth factors induce recruitment of monocytes to subintimal regions, smooth muscle proliferation and increased synthesis of matrix proteins. The recruited monocytes differentiate into macrophages, accumulate lipid and ultimately become foam cells. Together with accompanying T-lymphocytes, these changes represent the fatty streak, an early histopathological change indicating atherosclerosis. Progression of this atherosclerotic lesion is marked by the accumulation of alternating layers of smooth muscle cells and lipid-laden macrophages. The advanced lesions of atherosclerosis compromise the lumen diameter, reducing the blood flow in arteries and thus limiting kidney oxygenation.44–46,49–52 In the early stages of atherosclerotic renal artery stenosis progressive decreases in blood flow are accompanied by compensatory changes in arteriovenous shunting, and decreases in glomerular filtration rate and tubular reabsorption of sodium, that either increase oxygen availability or reduce its consumption. Within the whole kidney these adaptive mechanisms appear to maintain appropriate oxygenation.215 However, direct measurements of intrarenal tissue oxygenation demonstrate the induction of regional hypoxia in the cortex, but especially the medulla.216–218 This heterogenous pattern of intrarenal hypoxia likely results from inherent differences in the physiology and vasculature of the renal cortex and medulla.219 These cause stenosis to induce localized microvascular dysfunction and rarefaction, inflammation, oxidative stress, and/or fibrosis.219–223 While reductions in oxygen consumption can maintain whole-kidney oxygenation when renal artery stenosis is moderate, this compensatory mechanism becomes overwhelmed when vascular occlusion reaches between 70% and 80%. Under these circumstances cortical hypoxia is overt, leading to activation of the renin-angiotensin-aldosterone system, loss of kidney function, rarefaction of small renal vessels, kidney fibrosis, atrophy, and end stage kidney disease designated “ischemic nephropathy”.221,223,224–228 The connection between atherosclerosis-driven renal hypoxia and CKD is underscored by the finding that the preservation of microvascular architecture by intrarenal administration of vascular endothelial growth factor decreases renal fibrosis and maintains renal hemodynamics and function in an experimental model of renal artery stenosis.224 In addition, when femoropopliteal angioplasty restores the lumen diameter in patients with generalized atherosclerosis, the incidence of renal disease is dramatically reduced.43 Furthermore, several clinical trials have validated renal angioplasty and stenting in treating renal artery stenosis, especially in high-risk patients with recurrent flash pulmonary edema.229–231 Controversy exists as to whether kidney reoxygenation through this surgery is superior to that induced by medical therapy. Nevertheless, the goal of both strategies is to correct renal hypoxia. A goal reinforced by the practice guidelines of the American Heart Association and the American College of Cardiology Foundation that state the preferred treatment for hemodynamically significant renal artery stenosis is improved kidney oxygenation.49

Repeated Episodes of Acute Kidney Injury

Acute kidney injury (AKI) is the generic term for an abrupt and sustained decrease in renal function that can be reversible if treated promptly and appropriately.53 Most major causes of AKI produce conditions of hypoxia within the kidney. These include sepsis that induces renal vasoconstriction through the release of endothelin and the use of radiocontrast imaging dyes that increase oxygen consumption for solute reabsorption and reduce regional inner medullary blood flow.54–61 More generalized reductions in blood flow represent another major cause of AKI. These can result from hemorrhage, decompensated liver cirrhosis, treatment with non-steroidal anti-inflammatory drugs, congestive heart failure, and renal artery occlusion or stenosis.53 In addition, many forms of surgery where blood flow is inadvertently or deliberately reduced carry an inherent risk for the development of AKI.62–70 Inadvertent surgical reductions in blood flow can be caused by voluminous blood loss such as often occurs during major hepatic resections.64,69 Deliberate blood flow reduction is caused by the clamping of major blood vessels such as occurs during organ transplantation, cardiopulmonary bypass, and thoracoabdominal aneurysm surgery.63,65,66,70 Meta-analysis, epidemiological, and clinical follow-up studies have all shown a strong correlation between AKI episodes and subsequent development of CKD.232–236 This correlation is observed even in patients who regained normal renal function after AKI.237 Strikingly, both the severity and the number of AKI episodes are predictive of CKD development.238,239 These data, along with animal studies, have established a causal relationship between AKI and the subsequent development of CKD.240–242 Induction of AKI in animals by ischemia, radiocontrast agents, cisplatin, or rhabdomyolysis all induce oxygen tensions below 10 mm Hg deep within kidney tissue.95,243–247 In addition, impaired renal oxygenation has also been observed in human AKI.248 Importantly, renal hypoxia is found not only during the acute phase of AKI but also up to 5 weeks later, after the recovery phase.243,249,250 This sustained hypoxia results in the kidney down-regulating pro-angiogenic isoform 164 and up-regulating dys-angiogenic isoforms 120 and 188 of vascular endothelial growth factor A (VEGF-A).251,252 As a consequence, the vascular architecture of the kidney fails to be maintained with reductions in capillary number as well as individual capillary caliber and area.252–255 Thus, the initial hypoxia insult caused by an episode of AKI is consolidated by subsequent capillary rarefaction that reduces oxygen delivery. This chronic hypoxia then induces a slew of pathological processes in tubular epithelial cells including apoptosis, the prevention of redifferentiation after regeneration and conversion to myofibrolasts.256–260 Hypoxia also induces monocytes to express the β2 integrin family of adhesion molecules and kidney cells to express vascular cell adhesion molecule 1 and intracellular adhesion molecule 1 as well as the monocyte chemo-attractants C-C motif ligand 2 and C-X3-C motif ligand 1.252,261–264 These hypoxia-dependent changes in gene expression appear mediated in part by chromatin-remodeling, histone modification and the transcription factors HIF-1 and purine-rich binding protein alpha (Purα).261–265 Therefore, by inducing pro-inflammatory adhesion molecules and chemokines, hypoxia causes the accumulation of macrophages in the kidney that produce profibrotic cytokines such as transforming growth factor β and activate renal fibrobalsts.100,101,253 Hypoxia also activates fibroblasts directly to increase extracellular matrix deposition by increasing production of collagen and tissue inhibitor of metalloproteinase I and decreasing expression of collagenase.266 This activation of fibroblasts, along with the recruitment of inflammatory cells and the damage done to tubular epithelial cells, all lead to tubulointerstitial fibrosis. This fibrosis, in turn, aggravates hypoxia by increasing the distance between capillaries and tubular epithelial cells, leading to reduced oxygen diffusion efficiency.97 Consequently, hypoxia and tubulointerstitial fibrosis form a pathologic cycle that results in the progression of CKD (figure 1).242 The cycle is exacerbated by hypoxia-inducing gene-activating histone modifications that up-regulate expression of endothelin 1, thus, reducing oxygen delivery to the kidney by vasoconstriction.267,268

The hypoxia cycle driving chronic kidney disease. A constellation of environmental, behavioral, and physiologic risk factors reduce systemic oxygenation. In many cases these conditions exacerbate one another. Due to its vascular architecture and physiologic function, the kidney is particularly vulnerable to lowered oxygen tensions. This vulnerability is counteracted by defense mechanisms centered around activation of hypoxia-inducible factor. While these defense mechanisms are effective when periods of hypoxia are brief, they are overwhelmed when risk factors cause prolonged hypoxia. Under these circumstances a range of pathological cellular processes are activated, all of which aggravate renal hypoxia by metabolically consuming oxygen (red arrows). In addition, these processes cause renal fibrosis and vasoconstriction further aggravating hypoxia by limiting oxygen diffusion and reducing erythrocyte access (orange arrows). The net result is that a self-reinforcing cycle is established in which hypoxia causes cellular pathologies that themselves compromise renal oxygenation. The inevitable consequence of this cycle is progressive chronic kidney disease.
Figure 1

The hypoxia cycle driving chronic kidney disease. A constellation of environmental, behavioral, and physiologic risk factors reduce systemic oxygenation. In many cases these conditions exacerbate one another. Due to its vascular architecture and physiologic function, the kidney is particularly vulnerable to lowered oxygen tensions. This vulnerability is counteracted by defense mechanisms centered around activation of hypoxia-inducible factor. While these defense mechanisms are effective when periods of hypoxia are brief, they are overwhelmed when risk factors cause prolonged hypoxia. Under these circumstances a range of pathological cellular processes are activated, all of which aggravate renal hypoxia by metabolically consuming oxygen (red arrows). In addition, these processes cause renal fibrosis and vasoconstriction further aggravating hypoxia by limiting oxygen diffusion and reducing erythrocyte access (orange arrows). The net result is that a self-reinforcing cycle is established in which hypoxia causes cellular pathologies that themselves compromise renal oxygenation. The inevitable consequence of this cycle is progressive chronic kidney disease.

Sleep Apnea

Sleep apnea occurs in approximately 60% of patients with CKD.74–76 This prevalence is much higher than the 20% rate found in the general population.269 There are two main types of sleep apnea, termed obstructive and central.71–73 Obstructive sleep apnea is characterized by abnormal collapse of the pharyngeal airway, while central sleep apnea is characterized by a chronic lack of drive to breath. Sleep apneas are very common, affecting about 16% of men and 5% of women between 30 and 65 years-of-age. Cross-sectional cohort studies have demonstrated a significant direct association between the severity of sleep apnea and the severity of renal dysfunction.270–276 In addition, cohort studies of the longitudinal relationship between sleep apnea and kidney function show that apnea is independently associated with an increased risk of accelerated loss of kidney function.277,278 Conversely, as kidney function declines, the prevalence of sleep apnea and nocturnal hypoxia increases.272 Furthermore, aggressive dialysis has been found to improve obstructive sleep apnea. These findings have led to the contention that sleep apnea and CKD have a bidirectional relationship with both diseases being a risk factor for the other.279 CKD may lead to sleep apnea by autonomic nerve damage, effected by generalized uremic neuropathy, interfering with baroreceptor activity, pharyngeal narrowing due to fluid overload, and accumulation of uremic toxins.279–284 Sleep apnea likely causes CKD through numerous mechanisms that promote renal hypoxia.285,286 The most obvious mechanism is that apnea causes insufficient or absent ventilation, compromised gas exchange, and, thus, intermittent nocturnal hypoxia.77–81,83–86 Long-term exposure to these recurrent episodes of hypoxia-reoxygenation activate nicotinamide adenine dinucleotide phosphate-oxidase 2 that consumes oxygen through its generation of reactive oxygen species.287–291 Tissue damage effected by these species is augmented by intermittent hypoxia reducing renal expression of antioxidants.292 In addition, intermittent hypoxia induces the sympathetic nervous system to increase vascular resistance, down-regulates expression of the kallikrein-kallistatin vasodilator pathway, and activates the renal renin-angiotensin-aldosterone system to cause vasoconstriction.293–299 Together these processes conspire to produce renal fibrosis and sustained hypertension and their associated means of reducing renal oxygenation (figure 1).82,300–304 Oxygenation is further compromised by nocturnal hypoxia altering parasympathetic control of heart rate and inducing left ventricular hypertrophy.305,306 An additional consequence of sleep apnea is that it activates nuclear factor κB, initiating a cascade of events that include increased production of tumor necrosis factor α, interleukin 6, interleukin 8, interleukin 18, C-reactive protein, and C-C motif ligand 2.307–309 The resulting systemic inflammation, together with apnea-induced reactive oxygen species, hypertension, and platelet aggregability, drives the development of atherosclerosis and its mechanisms of generating renal hypoxia (figure 1). Indeed, chronic intermittent hypoxia linked with a high-fat diet has been shown to cause the de novo generation of atherosclerotic plaques.310 The profound consequences of atherosclerosis induced by sleep apnea are evident by it being an independent risk factor for cardiovascular mortality both in the general population and in patients with ESRD.76,84,311–316 Renal oxygenation is significantly improved by the treatment of sleep apnea with continuous positive airway pressure.81 This treatment also ameliorates glomerular hyperfiltration, improves endothelial function and survival, reduces the production of reactive oxygen species, C-reactive protein and interleukin 6, increases vasodilator levels, and decreases the levels of vasoconstrictors.81,83,87,317–322 That re-oxygenation has such a dramatic beneficial influence on renal function further underscores the intimate connection between renal hypoxia and the pathogenesis of CKD.

The Hypoxia Death Cycle

Environmental, behavioral, and pathophysiological risk factors each, in their own way, reduce systemic oxygenation or the specific oxygenation of the kidney. Many of these risk factors are inter-related, with one being a risk factor for the development of another. Consequently, a perfect storm of conditions can develop that pushes the pre-existing condition of low oxygen tension in the kidney into the realm of hypoxia (figure 1). When this occurs, renal cells initially respond with protective mechanisms that center around the phosphorylation of extracellular signal-regulated protein kinases 1 and 2 and the resulting stabilization of both HIF-1α and HIF-2α.94–96,292,323–325 These protective mechanisms include the up-regulation of pro-angiogenic factors such as isoform 164 of VEGF-A that protect against capillary rarefaction, and increased expression of matrix metalloproteinases that effect repair and protect against fibrosis by degrading extracellular matrix.326,327 In addition, short-term exposure to hypoxia leads to increased renal expression of antioxidants such as nuclear factor erythroid 2-related factor 2, hemeoxygenase 1, and metallothionein I that protect against fibrosis and inflammation induced by reactive oxygen species.94,292,328–330 However, when hypoxia is prolonged, there is an up-regulation of natural antisense HIF-1α that decreases HIF-1α expression by destabilizing its mRNA.331 In addition, increasing levels of reactive oxygen species target the HIF-1α protein for degradation through the ubiquitin-proteosome system.332,333 The expression of HIF-2α is unaffected by prolonged hypoxia, thus, there is a shift in the quanlitative nature of HIF away from subunit 1α and towards subunit 2α.331 This shift in HIF expression likely underlies the observation that under conditions of prolonged hypoxia the initial protective mechanisms of the kidney either fail to be engaged or are down-regulated.292,334,335 Thus, the expression of pro-angiogenic factors such as VEGF-A isoform 164 is repressed, and the expression of dys-angiogenic factors such as VEGF-A isoforms 120 and 188 is increased, causing capillary rarefaction.221,223,251,252 Fibrosis is driven by decreased expression of metalloproteinases and increased expression of their inhibitors and extracellular matrix proteins.336,337 Expression of antioxidants either fails to be induced or is decreased, allowing increased expression of reactive oxygen species to affect tubulointerstitial fibrosis through necrosis, apoptosis, activation of interstitial fibroblasts and pericytes, proliferation of endothelial cells, and epithelial-mesenchyme transition (figure 1).109–113,259,292,336–343 In addition, prolonged hypoxia causes renal endothelium to produce pro-inflammatory adhesion molecules, cytokines, and chemokines that activate macrophages already resident within the kidney and also recruit additional inflammatory cells from the circulation.344 Activated macrophages exacerbate the inflammatory process by producing additional cytokines such as tumor necrosis factor 1α and interleukin 6.345 Furthermore, they destroy renal tissue by phagocytosis and promote fibrosis by producing pro-fibrotic cytokines, such as transforming growth factor β1.346–348 The net result of prolonged hypoxia is that a vicious pathological cycle is initiated in which fibroblast and inflammatory cell activation combine with apoptosis, endothelial proliferation, and epithelial-mesenchymal transition to cause tubulointerstitial fibrosis. This fibrosis then further drives renal hypoxia by limiting oxygen diffusion. In addition, prolonged hypoxia also induces the renal cortex to up-regulate expression of the potent vasoconstrictor endothelin 1 and its type A receptor.268 Consequently, the kidney is further “suffocated” to CKD (Figure 1).97

A New Hypoxia Paradigm

The recruitment of inflammatory cells into the hypoxic kidney is driven by increased inter-cellular adhesion. This is totally dependent upon increased function of adhesion molecules expressed both on the surface of inflammatory cells and on the surface of kidney tissue.349 Critical adhesion molecules on the surface of renal tissue include the selectin and intercellular adhesion molecule families.350,351 Particularly critical on the leukocyte surface are the anti-adhesion molecules CD43 and CD45 and the β2-integrin family of pro-adhesion molecules.352–355 When leukocytes are not activated, they are maintained in the circulation by CD43 and CD45, which cover one-third of their surface and extend 45 nm and 55 nm, respectively, into the extracellular space.356,357 The extracellular domains of both CD43 and CD45 are heavily decorated with O-linked and N-linked carbohydrate moieties that often terminate in sialic acid.358 The strong negative charge conferred by this sialic acid, coupled with abundance and length, allow CD43 and CD45 to prevent leukocyte adhesion. When leukocytes are activated, there is a down-regulation of CD43 and CD45 along with a reduction in their sialylation and a concomitant up-regulation of the pro-adhesive β2-integrin family.358–363 The induction of this reciprocal expression of anti-adhesion and pro-adhesion forces results in leukocytes acquiring an adhesive phenotype capable of extravasation and infiltration into organs such as the kidney (figure 2).

Recruitment of inflammatory leukocytes into renal tissue. When leukocytes (orange spheres) are non-activated they are maintained in the circulation by repulsive forces conferred by CD43 and CD45 (blue ellipsoids) expressed on their surface. Leukocytes are activated by hypoxia either directly or indirectly as a result of responding to chemokines and cytokines released from hypoxic kidney tissue. The initial consequence of this activation is that the expression of anti-adhesive CD43 and CD45 is reduced allowing leukocytes to engage in fast-rolling along arterial cell walls (pink octahedrons) tethered by endothelial selectins (purple ellipsoids) binding leukocyte carbohydrate moieties. Fast-rolling is first slowed and then halted by β2-integrins (red ellipsoids) being induced on the leukocyte surface and binding endothelial extracellular matrix and intercellular adhesion molecules (ICAM-EXMX) (speckled purple ellipsoids). The β2-integrins subsequently mediate extravasation and chemotaxis through the traction they impart at the leukocyte leading-surface. Once embedded within renal tissue activated leukocytes drive fibrosis through phagocytosis, self-inflicted apoptosis and the release of cytokines and chemokines (orange arrowed-crosses) that induce the activation or apoptosis of surrounding cells and recruit additional inflammatory cells from the circulation. The vast majority of infiltrating inflammatory leukocytes eventually undergo apoptosis. However, a small proportion can remain resident with reduced β2-integrin expression and “memory” that allows rapid re-activation.
Figure 2

Recruitment of inflammatory leukocytes into renal tissue. When leukocytes (orange spheres) are non-activated they are maintained in the circulation by repulsive forces conferred by CD43 and CD45 (blue ellipsoids) expressed on their surface. Leukocytes are activated by hypoxia either directly or indirectly as a result of responding to chemokines and cytokines released from hypoxic kidney tissue. The initial consequence of this activation is that the expression of anti-adhesive CD43 and CD45 is reduced allowing leukocytes to engage in fast-rolling along arterial cell walls (pink octahedrons) tethered by endothelial selectins (purple ellipsoids) binding leukocyte carbohydrate moieties. Fast-rolling is first slowed and then halted by β2-integrins (red ellipsoids) being induced on the leukocyte surface and binding endothelial extracellular matrix and intercellular adhesion molecules (ICAM-EXMX) (speckled purple ellipsoids). The β2-integrins subsequently mediate extravasation and chemotaxis through the traction they impart at the leukocyte leading-surface. Once embedded within renal tissue activated leukocytes drive fibrosis through phagocytosis, self-inflicted apoptosis and the release of cytokines and chemokines (orange arrowed-crosses) that induce the activation or apoptosis of surrounding cells and recruit additional inflammatory cells from the circulation. The vast majority of infiltrating inflammatory leukocytes eventually undergo apoptosis. However, a small proportion can remain resident with reduced β2-integrin expression and “memory” that allows rapid re-activation.

The β2-integrin family comprises four heterodimers, composed of a common beta subunit encoded by the CD18 gene linked with one of four distinct alpha subunits encoded by the CD11a, CD11b, CD11c and CD11d genes.352,353 The CD11a/CD18 heterodimer is present on the surface of virtually all leukocytes, while CD11d/CD18 is expressed predominantly on myelomonocytic cells. CD11b/CD18 is expressed on natural killer and mature myeloid cells, and CD11c/CD18 expression mirrors that of CD11b/CD18, but also extends to dendritic cells, some cytotoxic T-lymphocyte clones, and some activated B and T-lymphocytes. Since the CD18 gene is active in all leukocytes, it is the more selective expression of the CD11 genes that dictates the specific cell-types on which the different CD11/CD18 heterodimers are present. The pattern of CD11 and CD18 production dictates that during activation macrophages exhibit induced expression of all four heterodimers that comprise the β2-integrin family.

The increase in β2-integrin function that occurs during leukocyte activation is caused by a number of mechanisms. The most rapid increase in function is caused by increased affinity and avidity of β2-integrin molecules already at the leukocyte surface.364 The next wave of increased function results from the mobilization to the leukocyte surface of premade pools of the β2-integrins.365 Finally, in order that leukocyte adhesion can be sustained, there is transcriptional induction of the β2-integrin genes.360

Since transcriptional induction of β2-integrin gene expression plays a vital role in macrophage function, work was undertaken to identify the causative molecular mechanisms.366–371 Using transfection analyses and phorbol myristate acetate, it was established for each β2-integrin gene that the proximal promoter region is sufficient to drive a pattern of inducible expression in vitro which mimics that of the endogenous gene in vivo.360 In subsequent studies it was determined that GA-binding proteins alpha and beta mediate induction of the CD18 gene,369 activator protein 1, specificity protein 1 and Purα mediate induction of the CD11c gene,368,371 myeloid specificity 2 and Purα mediate induction of the CD11a and CD11b genes,262,370 and Purα mediates induction of the CD11d gene.262

Despite β2-integrin expression being regulated at the transcriptional level, accepted dogma held that changes in β2-integrin expression relevant to leukocyte function occur almost exclusively after protein translation.364,365 This dogma was challenged by demonstrating that during hypoxia, transcription of the β2-integrin genes is absolutely required for leukocytes to exhibit increased adhesion to endothelium.261,262 A second dogma in the field of leukocyte function was that hypoxia induces their adhesion not as a consequence of their sensing oxygen deprivation directly but only indirectly as a consequence of sensing inflammatory cytokines released by hypoxic tissue.344–346 Again, this dogma was challenged by demonstrating that during hypoxia leukocytes exhibit an intrinsic increase in β2-integrin gene expression.261,262

Following activation by hypoxia, recent evidence indicates that leukocytes exacerbate the inflammatory microenvironment. Specifically, it has been demonstrated that during acute inflammatory disease, infiltrating neutrophils mold the tissue microenvironment in ways that significantly promote the stabilization of HIF.372 Microarray analysis of epithelial cells following β2-integrin-dependent neutrophil transmigration identified the induction of a prominent cohort of HIF target genes. These studies revealed that transmigrating neutrophils rapidly deplete the local environment of molecular oxygen and “transcriptionally imprint” the surrounding tissue to induce HIF target genes.

Taken together, recent studies establish a new paradigm in which leukocytes can sense hypoxia directly and respond by HIF-1 and Purα inducing transcription of the β2-integrin genes.261,262 Under normoxic conditions Purα has been shown to repress transcription of the CD43 gene.361,362 Consequently, this transcription factor appears to act as a master regulator, coordinating the reciprocal expression of anti-adhesion and pro-adhesion molecules to drive leukocyte adhesion. While hypoxia utilizes Purα to induce β2-integrin expression, it remains to be determined whether hypoxia represses expression of either CD43 or CD45, and if it does, whether Purα is involved. However, it is intriguing to note that the expression of both CD43 and CD45 is repressed under contitions of oxidative stress.373,374

Future Directions

It has been demonstrated experimentally that intrarenal hypoxia, per se, without confounding factors such as hyperglycemia and oxidative stress, can induce nephropathy.100,101 In addition, populations such as the Navajo Nation and Tibetans who live at high altitudes exhibit increased risk of developing CKD independent of glycemic control and lipidemia status.375,376 These findings, along with a host of other studies, argue strongly in favor of a causal relationship between hypoxia and CKD.88–101 As a consequence, there is increasing interest in the development of therapeutic strategies that target hypoxia and its dependent processes. Proof-of-principle of these strategies ranges from experiments performed in vitro, to testing in animals, to deployment in the clinic. The most evolved methodologies are those aimed at improving overall body oxygenation and counteracting artery narrowing. Systemic oxygenation strategies include the administration of erythropoietin to increase hematocrit levels, apparatus to effect continuous positive airway pressure, and whole-body chambers to produce an environment of 100% oxygen.81,83,87,110–112,377,378 Artery narrowing is already routinely counteracted by renal angioplasty with or without stenting and the administration of vasoconstriction inhibitors that target the renin-angiotensin-aldosterone system.49,379–381 The targeting of vasoconstriction pathways controlled through vasopressin, endothelin, and voltage dependent calcium channels are in their infancy, as is the use of vasodilators such as arginine and kallikrein.155,250,268,298,379,382,383 Beyond systemic hypo-oxygenation and vasoconstriction, the hypoxia-dependent processes of microvascular rarefaction, oxidative stress, leukocyte recruitment, and fibrosis all contribute to the development of CKD. A host of potential therapeutic targets exists within these areas (Table 1). However, efficacy remains proven predominantly only in vitro or in animals. A notable exception is in efforts to stabilize the expression of HIF-1α. During periods of brief hypoxia, this factor is induced and is renoprotective. Only when hypoxia is prolonged does HIF-1α become destabilized, leading to kidney damage. This phenomenon has been harnessed in the surgical setting by the development of the technique of remote ischemic preconditioning.384 Here repeated brief episodes of hypoxia are induced by artery clamping, stent balloon inflation, or applying a tourniquet or over-inflated blood-pressure cuff to an arm or lower limb. This procedure stabilizes HIF-1α in the kidney, thereby conferring protection against a subsequent period of prolonged hypoxia.385 Pre-conditioning by having cobalt chloride in drinking water or by breathing xenon, carbon monoxide, or isoflurane gas also stabilizes HIF-1α and confers renoprotection.386–390 The clear limitation of ischemic preconditioning is that it can only be deployed against a defined episode of acute hypoxia known to be imminent, such as occurs after artery clamping in transplant surgery, or the injection of radiocontrast medium. Consequently, effort has been applied to develop pharmacological stabilizers of HIF-1α that can be used to treat conditions characterized by prolonged chronic hypoxia. Dominant amongst these efforts has been the development of agents that work by inhibiting HIF-1α prolyl hydrolases (PHD).391 This family of three enzymes naturally down-regulate HIF-1α in a manner that is dependent upon 2-oxoglutarate. Pharmacological inactivation of the PHD enzymes by 2-oxoglutarate analogues is sufficient to stabilize HIF-1α, but it is nonspecific for individual PHD isoforms.392 Studies performed in vitro suggest these isoforms exhibit some significant differences in substrate specificity. PHD3, for example, does not hydroxylate proline 402 within the oxygen-dependent degradation domain of HIF-1α, while PHD1 and 2 do so efficiently.393,394 Such observations have generated significant interest in identifying PHD-modifying therapeutics, and a number of PHD inhibitors have been described. These include antagonists of alpha-keto-glutarate, analogs of naturally occurring cyclic hydroxamates, and direct inhibitors of the prolyl hydroxylases.392,395 The most mature work in this area is the development of the PHD inhibitor FG-4592.396 This agent stabilizes HIF-1α and is currently in phase 2 and 3 clinical trials for the treatment of anemia in patients with ESRD. The challenge for the future is to develop the full range of hypoxia targets that have demonstrated therapeutic potential in the laboratory (Table 1). Some that are already in clinical use are being applied in combination, such as dual inhibition of angiotensin receptors and angiotensin-converting enzyme.397 In addition, triple blockade of the aldosterone receptor, angiotensin-converting enzyme, and angiotensin receptors is also being evaluated.398 Other combinations, such as the simultaneous inhibition of angiotensin receptors and C-C chemokine receptor type 2, have proven more effective than monotherapy in animal models.399 Consequently, a future appears at hand when deployment of a personalized battery of therapeutics will deprive CKD of the hypoxia-driven forces that ferment its progression.

View this table:
Table 1

Targeting renal hypoxia: current and potential future treatments for chronic kidney disease

Footnotes

  • ↵1 Current affiliation: Leukemia Therapeutics LLC, Hull, MA

  • Received March 10, 2015.
  • Revision received July 15, 2015.
  • Revision received September 24, 2015.
  • Accepted September 30, 2015.

References

  1. 1
    ↵
    Fresenius Medical Care AG & Co. ESRD patients in 2012. A global perspective. Available at: http://www.vision-fmc.com/files/pdf_2/ESRD_Patients_2012.pdf. Accessed February 26, 2015.
  2. 2
    MoellerSGiobergeSBrownG. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002;17:2071–2076.
    Google ScholarCrossRefFull TextPubMedWeb of Science
  3. 3
    ↵
    AlebiosuCOAyodeleOE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418–423.
    Google ScholarPubMedWeb of Science
  4. 4
    ↵
    National Institutes of Health, National Institute of Diabetes & Digestive & Kidney Diseases, Division of Kidny, Urologic, & Hematologic Diseases. 2013 USRDS Annual Data Report. Volume 2. Atlas of end-stage renal disease in the United States. Available at: http://www.usrds.org/2013/pdf/v2_00_intro_13.pdf. Accessed February 26 2015
  5. 5
    ↵
    CoreshJAstorBCGreeneTEknoyanGLeveyAS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
    Google ScholarPubMedWeb of Science
  6. 6
    ↵
    AstorBCMuntnerPLevinAEustaceJACoreshJ. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2002;162:1401–1408.
    Google ScholarCrossRefPubMedWeb of Science
  7. 7
    IsekiKIkemiyaYIsekiCTakishitaS. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003;18:899–905.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  8. 8
    DeicherRHoriWH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003;12:139–143.
    Google ScholarCrossRefPubMedWeb of Science
  9. 9
    ↵
    BinleyKAskhamZIqballSSpearmanHMartinLde AlwisMThrasherAJAliRRMaxwellPHKingsmanSNaylorS. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002;100:2406–2413.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  10. 10
    ↵
    SusztakKRaffACSchifferMBöttingerEP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225–233.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  11. 11
    ↵
    PalmF. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin Exp Pharmacol Physiol 2006;33:997–1001.
    Google ScholarCrossRefPubMedWeb of Science
  12. 12
    ↵
    PalmFBuerkDGCarlssonPOHansellPLissP. Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: Effects on renal oxygenation and microcirculation. Diabetes 2005;54:3282–3287.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  13. 13
    ↵
    HeidlandAGerabekWSebekovaK. Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension. J Hum Hypertens 2001;15:5–16.
    Google ScholarCrossRefPubMed
  14. 14
    ↵
    WelchWJ. Intrarenal oxygen and hypertension. Clin Exp Pharmacol Physiol 2006;33:1002–1005.
    Google ScholarCrossRefPubMedWeb of Science
  15. 15
    ↵
    WelchWJBlauJXieHChabrashviliTWilcoxCS. Angiotensin-induced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol 2005;288:H22–H28.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  16. 16
    ↵
    WelchWJBaumgärtiHLübbersDWilcoxCS. Renal oxygenation defects in the spontaneously hypertensive rat: role of AT1 receptors. Kidney Int 2003;63:202–208.
    Google ScholarCrossRefPubMedWeb of Science
  17. 17
    ↵
    TanakaTMiyataTInagiRFujitaTNangakuM. Hypoxia in renal disease with proteinuria and/or glomerular hypertension. Am J Pathol 2004;165:1979–1992.
    Google ScholarCrossRefPubMedWeb of Science
  18. 18
    ↵
    BuchwaldHO’DeaTJMenchacaHJMichalekVNRohdeTD. Effect of plasma cholesterol on red blood cell oxygen transport. Clin Exp Pharmacol Physiol 2000;27:951–955.
    Google ScholarCrossRefPubMedWeb of Science
  19. 19
    MenchacaHJMichalekVNRohdeTDO’DeaTJBuchwaldH. Decreased blood oxygen diffusion in hypercholesterolemia. Surgery 1998;124:692–698.
    Google ScholarCrossRefPubMed
  20. 20
    ↵
    BuchwaldHMenchacaHJMichalekVNRohdeTDHunninghakeDBO’DeaTJ. Plasma cholesterol: an influencing factor in red blood cell oxygen release and cellular oxygen availability. J Am Coll Surg 2000;191:490–497.
    Google ScholarCrossRefPubMed
  21. 21
    ↵
    HeymanSNGoldfarbMRosenbergerCShinaARosenS. Effect of nicotine on the renal microcirculation in anesthetized rats: a potential for medullary hypoxic injury? Am J Nephrol 2005;25:226–232.
    Google ScholarCrossRefPubMedWeb of Science
  22. 22
    ↵
    OrthSRRitzE. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens 2002;11:483–488.
    Google ScholarCrossRefPubMedWeb of Science
  23. 23
    WessonDE. The relationship of cigarette smoking to end-stage renal disease. Semin Nephrol 2003;23:317–322.
    Google ScholarCrossRefPubMed
  24. 24
    ↵
    EjerbladEForedCMLindbladPFryzekJDickmanPWElinderCGMcLaughlinJKNyrénO. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol 2004;15:2178–2185.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  25. 25
    ↵
    RitzEBenckUFranekEKellerCSeyfarthMCloriusJ. Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease. J Am Soc Nephrol 1988;9:1798–1804.
    Google Scholar
  26. 26
    ↵
    HessW. [Affinity of oxygen for hemoglobin – its significance under physiological and pathological conditions.] [Article in German] Anaesthesist 1987;36:455–467.
    Google ScholarPubMed
  27. 27
    ↵
    UrbanettiJS. Carbon monoxide poisoning. Prog Clin Biol Res 1981;51:355–385.
    Google ScholarPubMed
  28. 28
    ↵
    SchwelaD. Air pollution and health in urban areas. Rev Environ Health 2000;15:13–42.
    Google ScholarPubMed
  29. 29
    ↵
    BadmanDGJaffeER. Blood and air pollution: state of knowledge and research needs. Otolaryngol Head Neck Surg 1996;114:205–208.
    Google ScholarCrossRefAbstract/Full TextPubMed
  30. 30
    ↵
    BrookRDBrookJRUrchBVincentRRajagopalanSSilvermanF. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation 2002;105:1534–1536.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  31. 31
    RundellKWHoffmanJRCavistonRBulbulianRHollenbachAM. Inhalation of ultrafine and fine particulate matter disrupts systemic vascular function. Inhal Toxicol 2007;19:133–140.
    Google ScholarCrossRefPubMedWeb of Science
  32. 32
    ↵
    SalviSBlombergARundellBKellyFSandstromTHolgateSTFrewA. (1999). Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med 1999;159:702–709.
    Google ScholarCrossRefPubMedWeb of Science
  33. 33
    ↵
    van EedenSFTanWCSuwaTMukaeHTerashimaTFujiiTQuiDVincentRHoggJC. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter in air pollutants (PM10). Am J Respir Crit Care Med 2001;164:826–830.
    Google ScholarCrossRefPubMedWeb of Science
  34. 34
    ↵
    WangXRChristianiDC. Respiratory symptoms and functional status in workers exposed to silica, asbestos, and coal mine dusts. J Occup Environ Med 2000;42:1076–1084.
    Google ScholarCrossRefPubMedWeb of Science
  35. 35
    ↵
    GoldsmithJRGoldsmithDF. Fiberglass or silica exposure and increased nephritis or ESRD (end-stage renal disease). Am J Ind Med 1993;23:873–881.
    Google ScholarCrossRefPubMed
  36. 36
    ↵
    MeoSAAl-DreesAM. Lung function among non-smoking wheat flour mill workers. Int J Occup Med Environ Health 2005;18:259–264.
    Google ScholarPubMed
  37. 37
    WangXRZhangHXSunBXDaiHLHangJQEisenEAWegmanDHOlenchockSAChristianiDC. A 20-year follow-up study on chronic respiratory effects of exposure to cotton dust. Eur Respir J 2005;26:881–886.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  38. 38
    Krysinska-TraczykESkorskaCPrazmoZSitkowskaJCholewaGDutkiewiczJ. Exposure to airborne microorganisms, dust and endotoxin during flax scutching on farms. Ann Agric Environ Med 2004;11:309–317.
    Google ScholarPubMedWeb of Science
  39. 39
    DutkiewiczJOlenchockSKrysinska-TraczykESkorskaCSitkowskaJPrazmoZ. Exposure to airborne microorganisms in fiberboard and chipboard factories. Ann Agric Environ Med 2001;8:191–199.
    Google ScholarPubMedWeb of Science
  40. 40
    ↵
    ShenYESorensonWGLewisDMOlenchockSA. Microbiological analysis and inflammatory effects of settled dusts from rice and hay. Biomed Environ Sci 1990;3:353–363.
    Google ScholarPubMed
  41. 41
    ↵
    HalatekTSinczuk-WalczakHJanasikBTrzcinka-OchockaMWinnickaRWasowiczW. Health effects and arsenic species in urine of copper smelter workers. J Environ Sci Health A Tox Hazard Subst Environ Eng 2014;49:787–797.
    Google ScholarCrossRefPubMed
  42. 42
    ↵
    LueSHWelleniusGAWilkerEHMostofskyEMittlemanMA. Residential proximity to major roadways and renal function. J Epidemiol Community Health 2013;67:629–634.
    Google ScholarCrossRefAbstract/Full TextPubMed
  43. 43
    ↵
    NovickACPohlMASchrieberMGiffordRWJrVidtDG. Revascularization for preservation of renal function in patients with atherosclerotic renovascular disease. J Urol 1983;129:907–912.
    Google ScholarPubMedWeb of Science
  44. 44
    ↵
    GainerJL. Hypoxia and atherosclerosis: re-evaluation of an old hypothesis. Atherosclerosis 1987;68:263–266.
    Google ScholarCrossRefPubMedWeb of Science
  45. 45
    ShanleyPF. The pathology of chronic renal ischemia. Semin Nephrol 1996;16:21–32.
    Google ScholarPubMedWeb of Science
  46. 46
    ↵
    JonoSShioiAIkariYNishizawaY. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006;24:176–181.
    Google ScholarCrossRefPubMedWeb of Science
  47. 47
    ↵
    McCulloughPA. Cardiorenal risk: an important clinical intersection. Rev Cardiovasc Med 2002;3:71–76.
    Google ScholarCrossRefPubMed
  48. 48
    ↵
    MassyZAKeaneWF. Pathogenesis of atherosclerosis. Semin Nephrol 1996;16:12–20.
    Google ScholarPubMedWeb of Science
  49. 49
    ↵
    AndersonJLHalperinJLAlbertNMBozkurtBBrindisRGCurtisLHDeMetsDGuytonRAHochmanJSKovacsRJOhmanEMPresslerSJSellkeFWShenWK. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2013;127:1425–1443.
    Google ScholarCrossRefFull TextPubMedWeb of Science
  50. 50
    NesbittESchmidt-TrucksassAIl’yasovKAWeberHHuonkerMLaubenbergerJKeulJHennigJLangerM. Assessment of arterial blood flow characteristics in normal and atherosclerotic vessels with fast Fourier flow method. MAGMA 2000;10:27–34.
    Google ScholarCrossRefPubMed
  51. 51
    WassermanSMMehrabanFKomuvesLGYangRBTomlinsonJEZhangYSpriggsFTopperJN. Gene expression profile of human endothelial cells exposed to sustained fluid shear stress. Physiol Genomics 2002;12:13–23.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  52. 52
    ↵
    KleinstreuerCHyunSBuchananJRJrLongestPWArchieJPJrTruskeyGA. Hemodynamic parameters and early intimal thickening in branching blood vessels. Crit Rev Biomed Eng 2001;29:1–64.
    Google ScholarCrossRefPubMedWeb of Science
  53. 53
    ↵
    LameireNVan BiesenWVanholderR. Acute renal failure. Lancet 2005;365:417–430.
    Google ScholarCrossRefPubMedWeb of Science
  54. 54
    ↵
    KlenzakJHimmelfarbJ. Sepsis and the kidney. Crit Care Clin 2005;21:211–222.
    Google ScholarCrossRefPubMedWeb of Science
  55. 55
    KonVBadrKF. Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int 1991;40:1–12.
    Google ScholarCrossRefPubMedWeb of Science
  56. 56
    HeymanSNReichmanJBrezisM. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:685–691.
    Google ScholarCrossRefPubMedWeb of Science
  57. 57
    HeymanSNRosenbergerCRosenS. Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005;20:i6–i11.
    Google ScholarCrossRefAbstractPubMedWeb of Science
  58. 58
    PrasadPVPriatnaASpokesKEpsteinFH. Changes in intrarenal oxygenation as evaluated by BOLD MRI in a rat kidney model for radiocontrast nephropathy. J Magn Reson Imaging 2001;13:744–747.
    Google ScholarCrossRefPubMedWeb of Science
  59. 59
    WeisbordSDPalevskyPM. Radiocontrast-induced acute renal failure. J Intensive Care Med 2005;20:63–75.
    Google ScholarCrossRefAbstract/Full TextPubMed
  60. 60
    HeymanSNBrezisMEpsteinFHSpokesKSilvaPRosenS. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991;40:632–642.
    Google ScholarCrossRefPubMedWeb of Science
  61. 61
    ↵
    LissPNygrenAEriksonUUlfendahlHR. Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 1998;53:698–702.
    Google ScholarCrossRefPubMedWeb of Science
  62. 62
    ↵
    CarmichaelPCarmichaelAR. Acute renal failure in the surgical setting. ANZ J Surg 2003;73:144–153.
    Google ScholarCrossRefPubMedWeb of Science
  63. 63
    ↵
    ManganoCMDiamondstoneLSRamsayJGAggarwalAHerskowitzAManganoDT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998;128:194–203.
    Google ScholarCrossRefPubMedWeb of Science
  64. 64
    ↵
    HellingTS. Ruminations of an ordinary hepatic surgeon: a journey through the pitfalls of major liver resections. J Gastrointest Surg 2002;6:625–629.
    Google ScholarCrossRefPubMed
  65. 65
    ↵
    ZvaraDA. Thoracoabdominal aneurysm surgery and the risk of paraplegia: contemporary practice and future directions. J Extra Corpor Technol 2002;34:11–17.
    Google ScholarPubMed
  66. 66
    ↵
    DragunDHoffUParkJKQunYSchneiderWLuftFCHallerH. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000;58:2166–2177.
    Google ScholarCrossRefPubMedWeb of Science
  67. 67
    WangWZAndersonGL. Intervention approaches against I/R-induced arterial insufficiency in reconstructive surgery. Hand Clin 2001;17:357–369.
    Google ScholarPubMed
  68. 68
    PadanilamBJLewingtonAJ. Molecular mechanisms of cell death and regeneration in acute ischemic renal injury. Curr Opin Nephrol Hypertens 1999;8:15–19.
    Google ScholarCrossRefPubMedWeb of Science
  69. 69
    ↵
    TakahamaT. [Post-operative complications after hepatopancreatoduodenectomy (HPD).] [Article in Japanese] Nippon Geka Gakkai Zasshi 2001;102:220–225.
    Google ScholarPubMed
  70. 70
    ↵
    HesselEA2nd Abdominal organ injury after cardiac surgery. Semin Cardiothorac Vasc Anesth 2004;8:243–263.
    Google ScholarCrossRefAbstract/Full TextPubMed
  71. 71
    ↵
    EckertDJJordanASMerchiaPMalhotraA. Central sleep apnea: Pathopysiology and treatment. Chest 2007;131:595–607.
    Google ScholarCrossRefPubMedWeb of Science
  72. 72
    WhiteDP. Sleep apnea. Proc Am Thorac Soc 2006;3:124–128.
    Google ScholarCrossRefPubMed
  73. 73
    ↵
    WiegandLZwillichCW. Obstructive sleep apnea. Dis Mon 1994;40:197–252.
    Google ScholarPubMed
  74. 74
    ↵
    KrausMAHamburgerRJ. Sleep apnea in renal failure. Adv Perit Dial 1997;13:88–92.
    Google ScholarPubMed
  75. 75
    PerlJUnruhMLChanCT. Sleep disorders in end-stage renal disease: ‘Markers of inadequate dialysis’? Kidney Int 2006;70:1687–1693.
    Google ScholarCrossRefPubMedWeb of Science
  76. 76
    ↵
    ZoccaliCMallamaciFTripepiG. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003;85(Suppl):S105–S110.
    Google ScholarCrossRef
  77. 77
    ↵
    PrabhakarNR. Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J Appl Physiol 2001;90:1986–1994.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  78. 78
    LahiriSDi GiulioCRoyA. Lessons from chronic intermittent and sustained hypoxia at high altitudes. Respir Physiol Neurobiol 2002;130:223–233.
    Google ScholarCrossRefPubMedWeb of Science
  79. 79
    LavieL. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev 2003;7:35–51.
    Google ScholarCrossRefPubMedWeb of Science
  80. 80
    ChiangAA. Obstructive sleep apnea and chronic intermittent hypoxia; a review. Chin J Physiol 2006;49:234–243.
    Google ScholarPubMedWeb of Science
  81. 81
    ↵
    SardoLPalangePDi MarioFBarbanoBGiganteAMordentiMSteffaninaABoniniMAmorosoAVaccaroFCianciR. Intrarenal hemodynamic and oxidative stress in patients with obstructive sleep apnea syndrome. Sleep Breath 2015;19:1205–1212.
    Google ScholarCrossRefPubMed
  82. 82
    ↵
    WeissJWLiuMDYHuangJ. Physiological basis for a causal relationship of obstructive sleep apnoea to hypertension. Exp Physiol 2007;92:21–26.
    Google ScholarCrossRefPubMedWeb of Science
  83. 83
    ↵
    PressmanMRBenzRLSchleiferCRPetersonDD. Sleep disordered breathing in ESRD: acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 1993;43:1134–1139.
    Google ScholarCrossRefPubMedWeb of Science
  84. 84
    ↵
    ZoccaliCMallamaciFTripepiG. Nocturnal hypoxemia: a neglected cardiovascular risk factor in end-stage renal disease? Blood Purif 2002;20:120–123.
    Google ScholarCrossRefPubMed
  85. 85
    Launois-RollinatS. [Harmful effects of chronic intermittent hypoxia. ] [Article in French] Rev Mal Respir 2006;23:7S116–7S119.
    Google ScholarPubMed
  86. 86
    ↵
    FosterGEPoulinMJHanlyPJ. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. Exp Physiol 2007;92:51–65.
    Google ScholarCrossRefPubMedWeb of Science
  87. 87
    ↵
    KinebuchiSKazamaJJSatohMSakaiKNakayamaHYoshizawaHNaritaISuzukiEGejyoF. Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnoea syndrome. Clin Sci 2004;107:317–322.
    Google ScholarCrossRefPubMed
  88. 88
    ↵
    FineLGBandyopadhayDNormanJT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000;75:S22–S26.
    Google ScholarCrossRefPubMed
  89. 89
    ↵
    EckardtKUBernhardtWMWeidemannAWarneckeCRosenbergerCWiesenerMSWilliamC. Role of hypoxia in the pathogenesis of renal disease. Kidney Int 2005;99(Suppl):S46–S51.
    Google Scholar
  90. 90
    NangakuM. Chronic hypoxia and tubulointestinal injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17–25.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  91. 91
    MatsumotoMTanakaTYamamotoTNoiriEMiyataTInagiRFujitaTNangakuM. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol 2004;15:1574–1581.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  92. 92
    NormanJTFineLG. Intrarenal oxygenation in chronic renal failure. Clin Exp Pharmacol Physiol 2006;33:989–996.
    Google ScholarCrossRefPubMedWeb of Science
  93. 93
    BrezisMRosenS. Hypoxia of the renal medulla-its implications for disease. N Engl J Med 1995;332:647–655.
    Google ScholarCrossRefPubMedWeb of Science
  94. 94
    ↵
    RosenbergerCRosenSShinaABernhardtWWiesenerMSFreiUEckardtKUHeymanSN. Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int 2006;70:60–70.
    Google ScholarCrossRefPubMedWeb of Science
  95. 95
    ↵
    HaaseVH. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int 2006;69:1302–1307.
    Google ScholarCrossRefPubMedWeb of Science
  96. 96
    ↵
    HeymanSNKhamaisiMRosenSRosenbergerC. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008;28:998–1006.
    Google ScholarCrossRefPubMedWeb of Science
  97. 97
    ↵
    MimuraINangakuM. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 2010;6:667–678.
    Google ScholarCrossRefPubMed
  98. 98
    OwCPAbdelkaderAHilliardLMPhillipsJKEvansRG. Determinants of renal tissue hypoxia in a rat model of polycystic kidney disease. Am J Physiol Regul Integr Comp Physiol 2014;307:R1207–R1215.
    Google ScholarCrossRefAbstract/Full TextPubMed
  99. 99
    ↵
    PalmFNordquistL. Renal tubulointerstitial hypoxia: cause and consequence of kidney dysfunction. Clin Exp Pharmacol Physiol 2011;38:474–480.
    Google ScholarCrossRefPubMed
  100. 100
    ↵
    Friederich-PerssonMThörnEHansellPNangakuMLevinMPalmF. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension 2013;62:914–919.
    Google ScholarCrossRefPubMed
  101. 101
    ↵
    Friederich-PerssonMPerssonPFaschingAHansellPNordquistLPalmF. Increased kidney metabolism as a pathway to kidney tissue hypoxia and damage: effects of triiodothyronine and dinitrophenol in normoglycemic rats. Adv Exp Med Biol 2013;789:9–14.
    Google ScholarCrossRefPubMed
  102. 102
    ↵
    BrezisMRosenSSilvaPEpsteinFH. Renal ischemia: a new perspective. Kidney Int 1984;26:375–383.
    Google ScholarCrossRefPubMedWeb of Science
  103. 103
    ↵
    LubbersDWBaumgärtlH. Heterogeneities and profiles of oxygen pressure in brain and kidney as examples of the pO2 distribution in the living tissue. Kidney Int 1997;51:372–380.
    Google ScholarCrossRefPubMedWeb of Science
  104. 104
    ↵
    SchurekHJJostUBaumgärtlHBertramHHeckmannU. Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. Am J Physiol 1990;259:F910–F915.
    Google ScholarWeb of Science
  105. 105
    ↵
    ZhangWEdwardsA. Oxygen transport across vasa recta in the renal medulla. Am J Physiol Heart Circ Physiol 2002;283:H1042–H1055.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  106. 106
    ↵
    ZimmerhacklBRobertsonCRJamisonRL. The microcirculation of the renal medulla. Circ Res 1985;57:657–667.
    Google ScholarCrossRefFull TextPubMedWeb of Science
  107. 107
    ↵
    PappeneimerJRKinterWB. Hematocrit ratio of blood within mammalian kidney and its significance for renal hemodynamics. Am J Physiol 1956;185:377–390.
    Google Scholar
  108. 108
    ↵
    UllrichKJPehlingGStoeckleH. [Hemoglobin concentration, erythrocyte count and hematocrit in the blood of the collecting tubules.] [Article in German] Pflugers Arch Gesamte Physiol Menschen Tiere. 1961;273:573–578.
    Google ScholarCrossRefPubMed
  109. 109
    ↵
    MaxwellPHOsmondMKPughCWHeryetANichollsLGTanCCDoeBGFergusonDJJohnsonMHRatcliffePJ. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993;44:1149–1162.
    Google ScholarCrossRefPubMedWeb of Science
  110. 110
    ↵
    AtesEYalcinAUYilmazSKokenTTokyolC. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg 2005;75:1100–1105.
    Google ScholarCrossRefPubMedWeb of Science
  111. 111
    JohnsonDWFormanCVeseyDA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology 2006;11:306–312.
    Google ScholarCrossRefPubMed
  112. 112
    ↵
    SongYRLeeTYouSJChinHJChaeDWLimCParkKHHanSKimJHNaKY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009;30:253–260.
    Google ScholarCrossRefPubMedWeb of Science
  113. 113
    ↵
    PatelNSAKerr-PetersonHLBrinesMCollinoMRogazzoMFantozziRWoodEGJohnsonFLYaqoobMMCeramiAThiemermannC. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med 2012;18:719–727.
    Google ScholarPubMed
  114. 114
    ↵
    ChattongSTanamaiJKiatsomchaiPNakatsuMSereemaspunAPimphaNPraditpornsilpaKRojanathanesRSethpakadeeATungsangaKEiam-OngSManothamK. Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production. Br. J. Pharmacol 2013;168:189–199.
    Google ScholarCrossRefPubMed
  115. 115
    ↵
    BrinesMGrassoGFiordalisoFSfacteriaAGhezziPFratelliMLatiniRXieQWSmartJSu-RickCJPobreEDiazDGomezDHandCColemanTCeramiA. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907–14912.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  116. 116
    ↵
    BreggiaACWojchowskiDMHimmelfarbJ. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am J Physiol Renal Physiol 2008;295:F1689–F1695.
    Google ScholarCrossRefAbstract/Full TextPubMed
  117. 117
    ↵
    RusaiKPrókaiASzebeniBFeketeATreszlAVannayAMüllerVReuszGHeemannULutzJTulassayTSzabóAJ. Role of serum and glucocorticoid-regulated kinase-1 in the protective effects of erythropoietin during renal ischemia/reperfusion injury. Biochem Pharmacol 2010;79:1173–1181.
    Google ScholarCrossRefPubMed
  118. 118
    ↵
    SharplesEJPatelNBrownPStewartKMota-PhilipeHSheaffMKieswichJAllenDHarwoodSRafteryMThiemermannCYaqoobMM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115–2124.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  119. 119
    SpandouETsouchnikasIKarkavelasGDounousiESimeonidouCGuiba-TziampiriOTsakirisD. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006;21:330–336.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  120. 120
    JohnsonDWPatBVeseyDAGuanZEndreZGobeGC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69:1806–1813.
    Google ScholarCrossRefPubMedWeb of Science
  121. 121
    ↵
    WangGHuangHWuHWuCXuYWangLLiuXWangCShenYLiDJungH. Erythropoietin attenuates cardiopulmonary bypass-induced renal inflammatory injury by inhibiting nuclear factor-κB p65 expression. Eur J Pharmacol 2012;689:154–159.
    Google ScholarCrossRefPubMed
  122. 122
    ↵
    HuLYangCZhaoTXuMTangQYangBRongRZhuT. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 2012;176:260–266.
    Google ScholarCrossRefPubMed
  123. 123
    ↵
    ArdalanMREstakhriRHajipourBAnsarinKAsiNANasirizadeMRAzarANGhorbanihaghjouAVatankhahAMEsmailiHA. Erythropoietin ameliorates oxidative stress and tissue injury following renal ischemia/reperfusion in rat kidney and lung. Med Princ Pract 2013;22:70–74.
    Google ScholarCrossRefPubMed
  124. 124
    ↵
    WittmannIMolnarGADegrellPWagnerZTamaskoMLaczyBBrasnyoPWagnerLNagyJ. Prevention and treatment of diabetic nephropathy. Diabetes Res Clin Pract 2005;68:S36–S42.
    Google Scholar
  125. 125
    ↵
    MogyorosiAZiyadehFN. Diabetic nephropathy. In: MassrySGGlassockRJ, eds. Textbook of Nephrology. 4th ed. Philadelphia: Lippincott, Williams and Wilkens; 2001. 845–895.
    Google Scholar
  126. 126
    ↵
    AyoSHRadnikRAGaroniJAGlassWFIIKreisbergJI. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990;136:1339–1348.
    Google ScholarPubMedWeb of Science
  127. 127
    NatarajanRGonzalesNXuLNadlerJ. Vascular smooth muscle cells exhibit increased growth response to elevated glucose. Biochem Biophys Res Commun 1992;87:552–560.
    Google Scholar
  128. 128
    WolfGSharmaKChenYEricksonMZiyadehFN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β1. Kidney Int 1992;42:647–656.
    Google ScholarCrossRefPubMedWeb of Science
  129. 129
    ↵
    SodhiCPPhadkeSABatlleDSahaiA. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol 2001;280:F667–F674.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  130. 130
    KoyaDKingGL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859–866.
    Google ScholarCrossRefAbstractPubMedWeb of Science
  131. 131
    TuckerMAChangPPrinceCGillespieGYMapstoneTB. TPA-mediated regulation of osteopontin in human malignant glioma cells. Anticancer Res 1998;18:807–812.
    Google ScholarPubMedWeb of Science
  132. 132
    TakemotoMYokoteKYamazakiMRidallALButlerWTMatsumotoTTamuraKSaitoYMoriS. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 1999;258:722–726.
    Google ScholarCrossRefPubMedWeb of Science
  133. 133
    ↵
    ParkCWKimJHLeeJHKimYSAhnHJShinYSKimSYChoiEJChangYSBangBK. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000;43:1544–1553.
    Google ScholarCrossRefPubMedWeb of Science
  134. 134
    ↵
    SodhiCPBatlleDSahaiA. Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells; role of PKC and p38 MAPKe. Kidney Int 2000;58:691–700.
    Google ScholarCrossRefPubMedWeb of Science
  135. 135
    ↵
    RuoslahtiEEngvallE. Integrins and vascular extracellular matrix assembly. J Clin Invest 1997;99:1149–1152.
    Google ScholarCrossRefPubMedWeb of Science
  136. 136
    ↵
    AllenTJCooperMELanHY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Atherscler Rep 2004;6:197–202.
    Google ScholarCrossRef
  137. 137
    CohenMPLautenslagerGTShearmanCT. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism 2001;50:1435–1440.
    Google ScholarCrossRefPubMedWeb of Science
  138. 138
    KoyaDHanedaMNakagawaHIsshikiKSatoHMaedaSSugimotoTYasudaHKashiwagiAWaysDKKingGLKikkawaR. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439–447.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  139. 139
    ↵
    ZiyadehFHoffmanBHanDIglesias-de la CruzCHongSIsonoMChenSMcGowenTSharmaK. Long-term prevention of renal insufficiency excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015–8020.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  140. 140
    ↵
    MakinoHMiyamotoYSawaiKMoriKMukoyamaMNakaoKYoshimasaYSugaSI. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006;55:2747–2756.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  141. 141
    ↵
    JohnsonRJFeigDINakagawaTSanchez-LozadaLGRodriguez-IturbeB. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008;26:381–391.
    Google ScholarCrossRefPubMedWeb of Science
  142. 142
    SalehMAPollockDM. Endothelin in renal inflammation and hypertension. Contrib Nephrol 2011;172:160–170.
    Google ScholarCrossRefPubMed
  143. 143
    ↵
    TianXYWongWTLeungFPZhangYWangYXLeeHKNgCFChenZYYaoXAuCLLauCWVanhouttePMCookeJPHuangY. Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats. Antioxid Redox Signal 2012;16:363–372.
    Google ScholarCrossRefPubMedWeb of Science
  144. 144
    ↵
    GomezSIWarnerLHaasJABoltermanRJTextorSCLermanLORomeroJC. Increased hypoxia and reduced renal tubular response to furosemide detected by BOLD magnetic resonance imaging in swine renovascular hypertension. Am J Physiol Renal Physiol 2009;297:F981–F986.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  145. 145
    ZhuQWangZXiaMLiPLVan TassellBWAbbateADhadukRLiN. Silencing of hypoxia-inducible factor-1α gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats. Hypertension 2011;58:657–664.
    Google ScholarCrossRef
  146. 146
    ↵
    AdlerSHuangH. Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats. J Am Soc Nephrol 2002;13:1788–1794.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  147. 147
    ↵
    BrezisMGreenfeldZShinaARosenS. Angiotensin II augments medullary hypoxia and predisposes to acute renal failure. Eur J Clin Invest 1990;20:199–207.
    Google ScholarCrossRefPubMedWeb of Science
  148. 148
    ↵
    HansellPWelchWJBlantzRCPalmF. Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. Clin Exp Pharmacol Physiol 2013;40:123–137.
    Google ScholarCrossRefPubMed
  149. 149
    ↵
    WelchWJMendoncaMAslamSWilcoxCS. Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension 2003;41:692–696.
    Google ScholarCrossRef
  150. 150
    ↵
    ZatzRBaylisC. Chronic nitric oxide inhibition model six years on. Hypertension 1998;32:958–964.
    Google ScholarCrossRef
  151. 151
    ↵
    SimãoSGomesPPintoVSilvaEAmaralJSIgrejaBAfonsoJSerrãoMPPinhoMJSoares-da-SilvaP. Age-related changes in renal expression of oxidant and antioxidant enzymes and oxidative stress markers in male SHR and WKY rats. Exp Gerontol 2011;46:468–474.
    Google ScholarCrossRefPubMed
  152. 152
    ↵
    ZhouXJVaziriNDZhangJWangHWWangXQ. Association of renal injury with nitric oxide deficiency in aged SHR. Prevention by hypertension control with AT1 blockade. Kidney Int 2002;62:914–921.
    Google ScholarCrossRefPubMedWeb of Science
  153. 153
    Mihailovic-StanojevicNMiloradovicZGrujic-MilanovicJIvanovMJovovicD. Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. Gen Physiol Biophys 2009;28:112–118.
    Google ScholarPubMed
  154. 154
    ↵
    PanicoCLuoZDamianoSArtigianoFGillPWelchWJ. Renal proximal tubular reabsorption is reduced in adult spontaneously hypertensive rats: roles of superoxide and Na+/H+ exchanger 3. Hypertension 2009;54:1291–1297.
    Google ScholarCrossRef
  155. 155
    ↵
    CamposSBOriMDóreaELSeguroAC. Protective effect of L-arginine on hypercholesterolemia-enhanced renal ischemic injury. Atherosclerosis 1999;143:327–334.
    Google ScholarCrossRefPubMed
  156. 156
    EconomidesPACaselliAZuoCSSparksCKhaodhiarLKatsilambrosNHortonESVevesA. Kidney oxygenation during water diuresis and endothelial function in patients with type 2 diabetes and subjects at risk to develop diabetes. Metabolism 2004;53:222–227.
    Google ScholarCrossRefPubMedWeb of Science
  157. 157
    ↵
    WangHTianJLFengSZSunNChenBYZhangY. The organ specificity in pathological damage of chronic intermittent hypoxia: an experimental study on rat with high-fat diet. Sleep Breath 2013;17:957–965.
    Google ScholarCrossRefPubMed
  158. 158
    ↵
    VeraniRR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 1992;20:629–634.
    Google ScholarCrossRefPubMedWeb of Science
  159. 159
    ↵
    CaballeroAEAroraSSaouafRLimSCSmakowskiPParkJYKingGLLoGerfoFWHortonESVevesA. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999;48:1856–1862.
    Google ScholarCrossRefAbstractPubMedWeb of Science
  160. 160
    ↵
    MichelakisEDHamplVNsairAWuXHarryGHaromyAGurtuRArcherSL. Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res 2002;90:1307–1315.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  161. 161
    ↵
    FavreauFRossardLZhangKDesurmontTManguyEBelliardAFabreSLiuJHanZThuillierRPapadopoulosVHauetT. Expression and modulation of translocator protein and its partners by hypoxia reoxygenation or ischemia and reperfusion in porcine renal models. Am J Physiol Renal Physiol 2009;297:F177–F190.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  162. 162
    ZagerRAJohnsonAAndersonKWrightS. Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury. Kidney Int 2001;59:1750–1761.
    Google ScholarCrossRefPubMedWeb of Science
  163. 163
    ↵
    ZagerRAAndohTBennettWM. Renal cholesterol accumulation: a durable response after acute and subacute renal insults. Am J Pathol 2001;159:743–752.
    Google ScholarCrossRefPubMedWeb of Science
  164. 164
    ↵
    BrownMSHoYKGoldsteinJL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem 1980;255:9344–9352.
    Google ScholarFull TextPubMedWeb of Science
  165. 165
    Dimitrova-ShumkovskaJVeenmanLRistoskiTLeschinerSGavishM. Chronic high fat, high cholesterol supplementation decreases 18 kDa translocator protein binding capacity in association with increased oxidative stress in rat liver and aorta. Food Chem Toxicol 2010;48:910–921.
    Google ScholarCrossRefPubMed
  166. 166
    LecanuLYaoZXMcCourtyASidahmedel-KOrellanaMEBurnierMNPapadopoulosV. Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO. Steroids 2013;78:137–146.
    Google ScholarCrossRefPubMedWeb of Science
  167. 167
    ↵
    LassanceLHaghiacMMiniumJCatalanoPHauguel-de MouzonS. Obesity-induced down-regulation of the mitochondrial trnslocator protein (TSPO) impairs placental steroid production. J Clin Endocrinol Metab 2015;100:E11–E18.
    Google ScholarCrossRefPubMed
  168. 168
    ↵
    Pinto-SietsmaSJMulderJJanssenWMHillegeHLde ZeeuwDde JongPE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000;133:585–591.
    Google ScholarCrossRefPubMedWeb of Science
  169. 169
    HalimiJMGiraudeauBVolSCacèsENivetHLebranchuYTichetJ. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000;58:1285–1292.
    Google ScholarCrossRefPubMedWeb of Science
  170. 170
    ↵
    YacoubRHabibHLahdoAAl AliRVarjabedianLAtallaGKassis AklNAldakheelSAlahdabSAlbitarS. Association between smoking and chronic kidney disease: a case control study. BMC Public Health 2010;10:731.
    Google ScholarCrossRefPubMed
  171. 171
    ↵
    Garcia-EsquinasELoefflerLFWeaverVMFadrowskiJJNavas-AcienA. Kidney function and tobacco smoke exposure in US adolescents. Pediatrics 2013;131:e1415–e1423.
    Google ScholarCrossRefAbstract/Full TextPubMed
  172. 172
    GambaroGVerlatoFBudakovicACasaraDSaladiniGDel PreteDBertagliaGMasieroMChecchettoSBaggioB. Renal impairment in chronic cigarette smokers. J Am Soc Nephrol 1998;9:562–567.
    Google ScholarAbstractPubMedWeb of Science
  173. 173
    BrigantiEMBranleyPChadbanSJShawJEMcNeilJJWelbornTAAtkinsRC. Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Australian Diabetes, Obesity and Lifestyle Study. Am J Kidney Dis 2002;40:704–712.
    Google ScholarCrossRefPubMedWeb of Science
  174. 174
    DülgerHDönderASekeroğluMRErkoçROzbayB. Investigation of the relationship between serum levels of cotinine and the renal function in active and passive smokers. Ren Fail 2011;33:475–479.
    Google ScholarCrossRefPubMed
  175. 175
    NoborisakaY. Smoking and chronic kidney disease in healthy populations. Nephrourol Mon 2013;5:655–667.
    Google ScholarPubMed
  176. 176
    ↵
    NoborisakaYIshizakiMYamadaYHondaRYokoyamaHMiyaoMTabataM. The effects of continuing and discontinuing smoking on the development of chronic kidney disease (CKD) in the healthy middle-aged working population in Japan. Environ Health Prev Med 2013; 18:24–32.
    Google ScholarCrossRefPubMed
  177. 177
    ↵
    GambaroGBaxGFusaroMNormannoMMananiSMZanellaMDangeloAFedeleDFavaroS. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 2001;14:337–342.
    Google ScholarPubMedWeb of Science
  178. 178
    HellemonsMEAgarwalPKvan der BijWVerschuurenEAPostmusDErasmusMENavisGJBakkerSJ. Former smoking is a risk factor for chronic kidney disease after lung transplantation. Am J Transplant 2011;11:2490–2498.
    Google ScholarCrossRefPubMed
  179. 179
    RegaladoMYangSWessonDE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000;35:687–694.
    Google ScholarCrossRefPubMedWeb of Science
  180. 180
    Míguez-BurbanoMJWyattCLewisJERodríguezADuncanR. Ignoring the obvious missing piece of chronic kidney disease in HIV: cigarette smoking. J Assoc Nurses AIDS Care 2010;21:16–24.
    Google ScholarCrossRefPubMed
  181. 181
    ↵
    TozawaMIsekiKIsekiCOshiroSIkemiyaYTakishitaS. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002;62:956–962.
    Google ScholarCrossRefPubMedWeb of Science
  182. 182
    AndronicoGRoméMLo CiceroAParsiRSeddioGFerraro-MortellaroRBuscemiSCerasolaG. Renal plasma flow, filtration fraction and microalbuminuria in hypertensive patients: effects of chronic smoking. Nephrology (Carlton) 2005;10:483–486.
    Google ScholarCrossRefPubMed
  183. 183
    ChuahirunTKhannaAKimballKWessonDE. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis 2003;41:13–21.
    Google ScholarCrossRefPubMedWeb of Science
  184. 184
    ChaseHPGargSKMarshallGBergCLHarrisSJacksonWEHammanRE. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991;265:614–617.
    Google ScholarCrossRefPubMedWeb of Science
  185. 185
    OzkokAAkpinarTSTufanFKanitezNAUysalMGuzelMCaliskanYAlisirSYaziciHEcderT. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clin Exp Nephrol 2013;17:345–351.
    Google ScholarCrossRefPubMed
  186. 186
    WardMMStudenskiS. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 1992;152:2082–2088.
    Google ScholarCrossRefPubMedWeb of Science
  187. 187
    ↵
    OrthSR. Smoking and the kidney. J Am Soc Nephrol 2002;13:1663–1672.
    Google ScholarCrossRefFull TextPubMed
  188. 188
    ↵
    KheradmandAShahbazianH. The role of pretransplant smoking on allograft survival in kidney recipients. Urol J 2005;2:36–39.
    Google ScholarPubMed
  189. 189
    ↵
    SungRSAlthoenMHowellTAOjoAOMerionRM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 2001;71:1752–1757.
    Google ScholarCrossRefPubMedWeb of Science
  190. 190
    ↵
    HallanSIOrthSR. Smoking is a risk factor in the progression to kidney failure. Kidney Int 2011;80:516–523.
    Google ScholarCrossRefPubMedWeb of Science
  191. 191
    ↵
    ManleyHJStackNM. Smoking cessation therapy considerations for patients with chronic kidney disease. Nephrol Nurs J 2008;35:357–363.
    Google ScholarPubMed
  192. 192
    ↵
    HuangMFLinWLMaYC. A study of reactive oxygen species in mainstream of cigarette. Indoor Air 2005;15:135–140.
    Google ScholarCrossRefPubMedWeb of Science
  193. 193
    ↵
    SatarugSMooreMR. Adverse health effects of chronic exposure to low-level cadmium in foodstuffs and cigarette smoke. Environ Health Perspect 2004;112:1099–1103.
    Google ScholarCrossRefPubMedWeb of Science
  194. 194
    ↵
    CooperRG. Effect of tobacco smoking on renal function. Indian J Med Res 2006;124:261–268.
    Google ScholarPubMedWeb of Science
  195. 195
    ↵
    JaimesEATianRXRaijL. Nicotine: the link between cigarette smoking and the progression of renal injury? Am J Physiol Heart Circ Physiol 2007;292:H76–H82.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  196. 196
    ↵
    JainGJaimesEA. Nicotine signaling and progression of chronic kidney disease in smokers. Biochem Pharmacol 2013;86:1215–1223.
    Google ScholarCrossRefPubMed
  197. 197
    RezonzewGChumleyPFengWHuaPSiegalGPJaimesEA. Nicotine exposure and the progression of chronic kidney disease: role of the α7-nicotinic acetylcholine receptor. Am J Physiol Renal Physiol 2012;303:F304–F312.
    Google ScholarCrossRefAbstract/Full TextPubMed
  198. 198
    ↵
    MacklinKDMausADPereiraEFAlbuquerqueEXConti-FineBM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1998;287:435–439.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  199. 199
    ↵
    UtsugisawaKNaganeYObaraDTohgiH. Increased expression of α7 nAChR after transient hypoxia in PC12 cells. Neuroreport 2000;11:2209–2212.
    Google ScholarCrossRefPubMed
  200. 200
    ↵
    MachaalaniRGhazaviEDavidRVHintonTMakrisAHennessyA. Nicotinic acetylcholine receptors (nAChR) are increased in the pre-eclamptic placenta. Hypertens Pregnancy 2015;34:227–240.
    Google ScholarCrossRefPubMed
  201. 201
    ↵
    AsanoHHorinouchiTMaiYSawadaOFujiiSNishiyaTMinamiMKatayamaTIwanagaTTeradaKMiwaS. Nicotine- and tar-free cigarette smoke induces cell damage through reactive oxygen species newly generated by PKC-dependent activation of NADPH oxidase. J Pharmacol Sci 2012;118:275–287.
    Google ScholarCrossRef
  202. 202
    JaimesEAGalceranJMRaijL. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775–784.
    Google ScholarCrossRefPubMedWeb of Science
  203. 203
    SharmaPEvansATParkerPJEvansFJ. NADPH-oxidase activation by protein kinase C-isotypes. Biochem Biophys Res Commun 1991;177:1033–1040.
    Google ScholarCrossRefPubMedWeb of Science
  204. 204
    ↵
    AranyIGrifoniSClarkJSCsongradiEMaricCJuncosLA. Chronic nicotine exposure exacerbates acute renal ischemic injury. Am J Physiol Renal Physiol 2011;301:F125–F133.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  205. 205
    ↵
    JaimesEADeMasterEGTianRXRaijL. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler Thromb Vasc Biol 2004;24:1031–1036.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  206. 206
    ↵
    JaimesEATianRXJoshiMSRaijL. Nicotine augments glomerular injury in a rat model of acute nephritis. Am J Nephrol 2009;29:319–326.
    Google ScholarCrossRefPubMedWeb of Science
  207. 207
    HuaPFengWJiSRaijLJaimesEA. Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol 2010;299:F732–F739.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  208. 208
    GorinYBlockKHernandezJBhandariBWagnerBBarnesJLAbboudHE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005;280:39616–39626.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  209. 209
    ObertDMHuaPPilkertonMEFengWJaimesEA. Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci 2011;341:126–130.
    Google ScholarCrossRefPubMed
  210. 210
    ↵
    AranyIReedDKGrifoniSCChandrashekarKBoozGWJuncosLA. A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury. Am J Physiol Renal Physiol 2012;302:F722–F729.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  211. 211
    ↵
    OrthSR. Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol 2004;15 Suppl 1:S58–S63.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  212. 212
    HalimiJMGiraudeauBVolSCacèsENivetHTichetJ. The risk of hypertension in men: direct and indirect effects of chronic smoking. J Hypertens 2002;20:187–193.
    Google ScholarCrossRefPubMedWeb of Science
  213. 213
    ↵
    MannSJJamesGDWangRSPickeringTG. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. JAMA 1991;265:2226–2228.
    Google ScholarCrossRefPubMedWeb of Science
  214. 214
    ↵
    BoorPCasperSCelecPHurbánkováMBenoMHeidlandAAmannKSebekováK. Renal, vascular and cardiac fibrosis in rats exposed to passive smoking and industrial dust fibre amosite. J Cell Mol Med 2009;13:4484–4491.
    Google ScholarCrossRefPubMed
  215. 215
    ↵
    EvansRGGoddardDEppelGAO’ConnorPM. Stability of tissue PO2 in the face of altered perfusion: a phenomenon specific to the renal cortex and independent of resting renal oxygen consumption. Clin Exp Pharmacol Physiol 2011;38:247–254.
    Google ScholarCrossRefPubMed
  216. 216
    ↵
    WarnerLGomezSIBoltermanRHaasJABentleyMDLermanLORomeroJC. Regional decreases in renal oxygenation during graded acute renal arterial stenosis: a case for renal ischemia. Am J Physiol Regul Integr Comp Physiol 2009;296:R67–R71.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  217. 217
    TextorSCGlocknerJFLermanLOMisraSMcKusickMARiedererSJGrandeJPGomezSIRomeroJC. The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J Am Soc Nephrol 2008;19:780–788.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  218. 218
    ↵
    GloviczkiMLSaadATextorSC. Blood oxygen level-dependent (BOLD) MRI analysis in atherosclerotic renal artery stenosis. Curr Opin Nephrol Hypertens 2013;22:519–524.
    Google ScholarCrossRefPubMed
  219. 219
    ↵
    EvansRGEppelGAAndersonWPDentonKM. Mechanisms underlying the differential control of blood flow in the renal medulla and cortex. J Hypertens 2004;22:1439–1451.
    Google ScholarCrossRefPubMedWeb of Science
  220. 220
    LermanLOTextorSCGrandeJP. Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond. Prog Cardiovasc Dis 2009;52:196–203.
    Google ScholarCrossRefPubMedWeb of Science
  221. 221
    ↵
    ZhuXYChadeARRodriguez-PorcelMBentleyMDRitmanELLermanALermanLO. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004;24:1854–1859.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  222. 222
    ChadeARMushinOPXhuXRodriguez-PorcelMGrandeJPTextorSCLermanALermanLO. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension 2005;46:772–779.
    Google ScholarCrossRefPubMed
  223. 223
    ↵
    ChadeARZhuXMushinOPNepoliCLermanALermanLO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 2006;20:1706–1708.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  224. 224
    ↵
    IliescuRFernandezSRKelsenSMaricCChadeAR. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 2010;25:1079–1087.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  225. 225
    KangDHJohnsonRJ. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003;12:43–49.
    Google ScholarCrossRefPubMedWeb of Science
  226. 226
    TextorSCLermanL. Renovascular hypertension and ischemic nephropathy. Am J Hypertens 2010;23:1159–1169.
    Google ScholarCrossRefAbstract/Full TextPubMed
  227. 227
    GloviczkiMLGlocknerJFCraneJAMcKusickMAMisraSGrandeJPLermanLOTextorSC. Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease. Hypertension 2011;58:1066–1072.
    Google ScholarCrossRef
  228. 228
    ↵
    GloviczkiMLKeddisMTGarovicVDFriedmanHHerrmannSMcKusickMAMisraSGrandeJPLermanLOTextorSC. TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis. Clin J Am Soc Nephrol 2013;8:546–553.
    Google ScholarCrossRefAbstract/Full TextPubMed
  229. 229
    ↵
    MurphyTPCooperCJDworkinLDHenrichWLRundbackJHMatsumotoAHJamersonKAD’AgostinoRB. The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. J Vasc Interv Radiol 2005;16:1295–1300.
    Google ScholarCrossRefPubMedWeb of Science
  230. 230
    BaxLMaliWPBuskensEKoomansHABeutlerJJBraamBBeekFJRabelinkTJPostmaCTHuysmansFTDeinumJThienTSchultze KoolLJWoittiezAJKouwenbergJJvan den MeirackerAHPattynamaPMvan de VenPJVroegindeweijDDoorenbosCJAartsJCKroonAAde LeeuwPWde HaanMWvan EngelshovenJMRuttenMJvan MontfransGAReekersJAPlouinPFLa Batide AlanoreAAziziMRaynaudAHardenPNCowlingM; STAR Study Group. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. J Nephrol 2003;16:807–812.
    Google ScholarPubMedWeb of Science
  231. 231
    ↵
    MistrySIvesNHardingJFitzpatrick-EllisKLipkinGKalraPAMossJWheatleyK. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. J Hum Hypertens 2007;21:511–515.
    Google ScholarCrossRefPubMedWeb of Science
  232. 232
    ↵
    AskenaziDJFeigDIGrahamNMHui-StickleSGoldsteinSL. 3–5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006;69:184–189.
    Google ScholarCrossRefPubMedWeb of Science
  233. 233
    CocaSGSinganamalaSParikhCR. Chronic kidney disease after acute kidney injury: a systemic review and meta-analysis. Kidney Int 2012;81:442–448.
    Google ScholarCrossRefPubMedWeb of Science
  234. 234
    MammenCAl AbbasASkippenPNadelHLevineDColletJPMatsellDG. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 2012;59:523–530.
    Google ScholarCrossRefPubMedWeb of Science
  235. 235
    WaldRQuinnRRAdhikariNKBurnsKEFriedrichJOGargAXHarelZHladunewichMALuoJMamdaniMPerlJRayJG; University of Toronto Acute Kidney Injury Research Group. Risk of chronic dialysis and death following acute kidney injury. Am J Med 2012;125:585–593.
    Google ScholarCrossRefPubMed
  236. 236
    ↵
    WaldRQuinnRRLuoJLiPScalesDCMamdaniMMRayJG; University of Toronto Acute Kidney Injury Research Group. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009;302:1179–1185.
    Google ScholarCrossRefPubMedWeb of Science
  237. 237
    ↵
    BucaloiuIDKirchnerHLNorfolkERHartleJEPerkinsRM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012;81:477–485.
    Google ScholarCrossRefPubMedWeb of Science
  238. 238
    ↵
    ChawlaLSAmdurRLAmodeoSKimmelPLPalantCE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011;79:1361–1369.
    Google ScholarCrossRefPubMedWeb of Science
  239. 239
    ↵
    ThakarCVChristiansonAHimmelfarbJLeonardAC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011;6:2567–2572.
    Google ScholarCrossRefAbstract/Full TextPubMed
  240. 240
    ↵
    BelayevLYPalevskyPM. The link between acute kidney injury and chronic kidney disease. Curr Opin Nephrol Hypertens 2014;23:149–154.
    Google ScholarCrossRefPubMed
  241. 241
    HsuCY. Yes, AKI truly leads to CKD. J Am Soc Nephrol 2012;23:967–969.
    Google ScholarCrossRefFull TextPubMedWeb of Science
  242. 242
    ↵
    TanakaSTanakaTNangakuM. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol 2014;307:F1187–F1195.
    Google ScholarCrossRefAbstract/Full TextPubMed
  243. 243
    ↵
    CondeEAlegreLBlanco-SánchezISáenz-MoralesDAguado-FraileEPonteBRamosESáizAJiménezCOrdoñezALópez-CabreraMdel PesoLde LandázuriMOLiañoFSelgasRSanchez-TomeroJAGarcía-BermejoML. Hypoxia inducible factor 1-alpha (HIF-1 alpha) is induced during reperfusion after renal ischemia and is critical for proximal tubule cell survival. PLoS One 2012;7:e33258.
    Google ScholarCrossRefPubMed
  244. 244
    ↵
    HillPShuklaDTranMGAragonesJCookHTCarmelietPMaxwellPH. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2008;19:39–46.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  245. 245
    RosenbergerCGoldfarbMShinaABachmannSFreiUEckardtKUSchraderTRosenSHeymanSN. Evidence for sustained renal hypoxia and transient hypoxia adaptation in experimental rhabdomyolysis-induced acute kidney injury. Nephrol Dial Transplant 2008;23:1135–1143.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  246. 246
    TanakaTKojimaIOhseTInagiRMiyataTIngelfingerJRFujitaTNangakuM. Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2005;289:F1123–F1133.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  247. 247
    ↵
    AbdelkaderAHoJOwCPEppelGARajapakseNWSchlaichMPEvansRG. Renal oxygenation in acute renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2014;306:F1026–F1038.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  248. 248
    ↵
    RedforsBBragadottirGSellgrenJSwärdKRickstenSE. Acute renal failure is NOT an “acute renal success” - a clinical study on the renal oxygen supply/demand relationship in acute kidney injury. Crit Care Med 2010;38:1695–1701.
    Google ScholarCrossRefPubMedWeb of Science
  249. 249
    ↵
    RosenbergerCPratschkeJRudolphBHeymanSNSchindlerRBabelNEckardtKUFreiURosenSReinkeP. Immunohistochemical detection of hypoxia-inducible factor-1 alpha in human renal allograft biopsies. J Am Soc Nephrol 2007;18:343–351.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  250. 250
    ↵
    BasileDPDonohoeDLRoetheKMattsonDL. Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage. Am J Physiol Renal Physiol 2003;284:F338–F348.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  251. 251
    ↵
    BasileDPFredrichKChelladuraiBLeonardECParrishAR. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol 2008;294:F928–F936.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  252. 252
    ↵
    LinSLChangFCSchrimpfCChenYTWuCFWuVCChiangWCKuhnertFKuoCJChenYMWuKDTsaiTJDuffieldJS. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011;178:911–923.
    Google ScholarCrossRefPubMedWeb of Science
  253. 253
    ↵
    BasileDPDonohoeDRoetheKOsbornJL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001;281:F887–F899.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  254. 254
    KramannRTanakaMHumphreysBD. Fluorescence microangiography for quantitative assessment of peritubular capillary changes after AKI in mice. J Am Soc Nephrol 2014;25:1924–1931.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  255. 255
    ↵
    MayerG. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 2011;26:1132–1137.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  256. 256
    ↵
    AsadaNTakaseMNakamuraJOguchiAAsadaMSuzukiNYamamuraKNagoshiNShibataSRaoTNFehlingHJFukatsuAMinegishiNKitaTKimuraTOkanoHYamamotoMYanagitaM. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011;121:3981–3990.
    Google ScholarCrossRefPubMedWeb of Science
  257. 257
    KhanSClevelandRPKochCJSchellingJR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999;79:1089–1099.
    Google ScholarPubMedWeb of Science
  258. 258
    LeBleuVSTaduriGO’ConnellJTengYCookeVGWodaCSugimotoHKalluriR. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013;19:1047–1053.
    Google ScholarCrossRefPubMed
  259. 259
    ↵
    ManothamKTanakaTMatsumotoMOhseTInagiRMiyataTKurokawaKFujitaTIngelfingerJRNangakuM. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004;65:871–880.
    Google ScholarCrossRefPubMedWeb of Science
  260. 260
    ↵
    PolichnowskiAJLanRGengHGriffinKAVenkatachalamMABidaniAK. Severe renal mass reduction impairs recovery and promotes fibrosis after AKI. J Am Soc Nephrol 2014;25:1496–1507.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  261. 261
    ↵
    KongTEltzschigHKKarhausenJColganSPShelleyCS. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc Natl Acad Sci USA 2004;101:10440–10445.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  262. 262
    ↵
    KongTScullyMShelleyCSColganSP. Identification of Pur alpha as a new hypoxia response factor responsible for coordinated induction of the beta 2 integrin family. J Immunol 2007;179:1934–1941.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  263. 263
    ZagerRAJohnsonACBeckerK. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and “end-stage” kidney disease. Am J Physiol Renal Physiol 2011;301:F1334–F1345.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  264. 264
    ↵
    ZagerRAJohnsonAC. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/profibrotic genes. Am J Physiol Renal Physiol 2009;296:F1032–F1041.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  265. 265
    ↵
    NaitoMZagerRABomsztykK. BRG1 increases transcription of proinflammatory genes in renal ischemia. J Am Soc Nephrol 2009;20:1787–1796.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  266. 266
    ↵
    NormanJTClarkIMGarciaPL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351–2366.
    Google ScholarCrossRefPubMedWeb of Science
  267. 267
    ↵
    JohnsonABDenkoNBartonMC. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat Res 2008;640:174–179.
    Google ScholarCrossRefPubMedWeb of Science
  268. 268
    ↵
    ZagerRAJohnsonACAndressDBeckerK. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 2013;84:703–712.
    Google ScholarCrossRefPubMedWeb of Science
  269. 269
    ↵
    YoungTPaltaMDempseyJSkatrudJWeberSBadrS. The occurrence of sleep-disordered breathing among middle-aged adults. N Eng J Med 1993;328:1230–1235.
    Google ScholarCrossRefPubMedWeb of Science
  270. 270
    ↵
    MarkouNKanakakiMMyrianthefsPHadjiyanakosDVlassopoulosDDamianosASiamopoulosKVasiliouMKonstantopoulosS. Sleep-disordered breathing in nondialyzed patients with chronic renal failure. Lung 2006;184:43–49.
    Google ScholarCrossRefPubMedWeb of Science
  271. 271
    SakaguchiYShojiTKawabataHNiihataKSuzukiAKanekoTOkadaNIsakaYRakugiHTsubakiharaY. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol 2011;6:995–1000.
    Google ScholarCrossRefAbstract/Full TextPubMed
  272. 272
    ↵
    NichollDDAhmedSBLoewenAHHemmelgarnBRSolaDYBeecroftJMTurinTCHanlyPJ. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest 2012;141:1422–1430.
    Google ScholarCrossRefPubMedWeb of Science
  273. 273
    KanbayABuyukoglanHOzdoganNKayaEOymakFSGulmezIDemirRKokturkOCovicA. Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. Int Urol Nephrol 2012;44:535–539.
    Google ScholarCrossRefPubMed
  274. 274
    FleischmannGFillaferGMattererHSkrabalFKotankoP. Prevalence of chronic kidney disease in patients with suspected sleep apnoea. Nephrol Dial Transplant 2010;25:181–186.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  275. 275
    CasserlyLFChowNAliSGottliebDJEpsteinLJKaufmanJS. Proteinuria in obstructive sleep apnea. Kidney Int 2001;60:1484–1489.
    Google ScholarCrossRefPubMedWeb of Science
  276. 276
    ↵
    FaulxMDStorfer-IsserAKirchnerHLJennyNSTracyRPRedlineS. Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep 2007;30:923–929.
    Google ScholarPubMedWeb of Science
  277. 277
    ↵
    AhmedSBRonksleyPEHemmelgarnBRTsaiWHMannsBJTonelliMKlarenbachSWChinRClementFMHanlyPJ. Nocturnal hypoxia and loss of kidney function. PLoS One 2011;6:e19029.
    Google ScholarCrossRefPubMed
  278. 278
    ↵
    SakaguchiYHattaTHayashiTShojiTSuzukiATomidaKOkadaNRakugiHIsakaYTsubakiharaY. Association of nocturnal hypoxemia with progression of CKD. Clin J Am Soc Nephrol 2013;8:1502–1507.
    Google ScholarCrossRefAbstract/Full TextPubMed
  279. 279
    ↵
    AbuyassinBSharmaKAyasNTLaherI. Obstructive sleep apnea and kidney disease: a potential bidirectional relationship. J Clin Sleep Med 2015;11:915–924.
    Google ScholarPubMed
  280. 280
    KershESKronfieldSJUnderAPopperRWCantorSCohnK. Autonomic insufficiency in uremia as a cause of hemodialysis-induced hypotension. N Eng J Med 1974;290:650–653.
    Google ScholarCrossRefPubMedWeb of Science
  281. 281
    HenrichWL. Hemodynamic instability during hemodialysis. Kidney Int 1986;30:605–612.
    Google ScholarCrossRefPubMedWeb of Science
  282. 282
    BeecroftJMHoffsteinVPierratosAChanCTMcFarlanePAHanlyPJ. Pharyngeal narrowing in end-stage renal disease: implications for obstructive sleep apnoea. Eur Respir J 2007;30:965–971.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  283. 283
    TangSCLamBLaiASPangCBTsoWKKhongPLIpMSLaiKN. Improvement in sleep apnea during nocturnal peritoneal dialysis is associated with reduced airway congestion and better uremic clearance. Clin J Am Soc Nephrol 2009;4:410–418.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  284. 284
    ↵
    TangSCLamBLamJCChanCKChowCCHoYWIpMSLaiKN. Impact of nephrotic edema of the lower limbs on obstructive sleep apnea: gathering a unifying concept for the pathogenetic role of nocturnal rostral fluid shift. Nephrol Dial Transplant 2012;27:2788–2794.
    Google ScholarCrossRefAbstract/Full TextPubMed
  285. 285
    ↵
    AdeseunGARosasSE. The impact of obstructive sleep apnea on chronic kidney disease. Curr Hypertens Rep 2010;12:378–383.
    Google ScholarCrossRefPubMed
  286. 286
    ↵
    HanlyPJAhmedSB. Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease? Chest 2014;146:1114–1122.
    Google ScholarCrossRefPubMed
  287. 287
    ↵
    PengYJOverholtJLKlineDKumarGKPrabhakarNR. Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. Proc Natl Acad Sci USA 2003;100:10073–10078.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  288. 288
    PengYJYuanGRamakrishnanDSharmaSDBosch-MarceMKumarGKSemenzaGLPrabhakarNR. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006;577:705–716.
    Google ScholarCrossRefPubMedWeb of Science
  289. 289
    YuanGKhanSALuoWNanduriJSemenzaGLPrabhakarNR. Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia. J Cell Physiol 2011;226:2925–2933.
    Google ScholarCrossRefPubMed
  290. 290
    YamauchiMNakanoHMaekawaJOkamotoYOhnishiYSuzukiTKimuraH. Oxidative stress in obstructive sleep apnea. Chest 2005;127:1674–1679.
    Google ScholarCrossRefPubMedWeb of Science
  291. 291
    ↵
    PialouxVHanlyPJFosterGEBrugniauxJVBeaudinAEHartmannSEPunMDugganCTPoulinMJ. Effects of exposure to intermittent hypoxia on oxidative stress and acute hypoxic ventilatory response in humans. Am J Respir Crit Care Med 2009;180:1002–1009.
    Google ScholarCrossRefPubMedWeb of Science
  292. 292
    ↵
    SunWYinXWangYTanYCaiLWangBCaiJFuY. Intermittent hypoxia-induced renal antioxidants and oxidative damage in male mice: hormetic dose response. Dose Response 2013;11:385–400.
    Google ScholarCrossRef
  293. 293
    ↵
    GilmartinGSLynchMTamisierRWeissJW. Chronic intermittent hypoxia in humans during 28 nights results in blood pressure elevation and increased muscle sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2010;299:H925–H931.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  294. 294
    FosterGEHanlyPJAhmedSBBeaudinAEPialouxVPoulinMJ. Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism. Hypertension 2010;56:369–377.
    Google ScholarCrossRefPubMed
  295. 295
    Pratt-UbunamaMNNishizakaMKBoedefeldRLCofieldSSHardingSMCalhounDA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007;131:453–459.
    Google ScholarCrossRefPubMedWeb of Science
  296. 296
    ZaluckyAANichollDDHanlyPJPoulinMJTurinTCWaljiSHandleyGBRaneriJKSolaDYAhmedSB. Nocturnal hypoxemia severity ands renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med 2015;192:873–880.
    Google ScholarCrossRefPubMed
  297. 297
    PerryJCBergamaschiCTCamposRRAndersenMLCasariniDETufikS. Differential sympathetic activation induced by intermittent hypoxia and sleep loss in rats: action of angiotensin (1–7). Auton Neurosci 2011;160:32–36.
    Google ScholarCrossRefPubMed
  298. 298
    ↵
    ThongboonkerdVGozalESachlebenLRJrArthurJMPierceWMCaiJChaoJBaderMPesqueroJBGozalDKleinJB. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem 2002;277:34708–34716.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  299. 299
    ↵
    BudhirajaRParthasarathySQuanSF. Endothelial dysfunction in obstructive sleep apnea. J Clin Sleep Med 2007;3:409–415.
    Google ScholarPubMed
  300. 300
    ↵
    PeppardPEYoungTPaltaMSkatrudJ. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378–1384.
    Google ScholarCrossRefPubMedWeb of Science
  301. 301
    DragerLFBortolottoLAFigueiredoACSilvaBCKriegerEMLorenzi-FilhoG. Obstructive sleep apnea, hypertension, and their interaction on arterial stiffness and heart remodeling. Chest 2007;131:1379–1386.
    Google ScholarCrossRefPubMedWeb of Science
  302. 302
    FletcherEC. Invited review: physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol 2001;90:1600–1605.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  303. 303
    MorganBJ. Vascular consequences of intermittent hypoxia. Adv Exp Med Biol 2007;618:69–84.
    Google ScholarCrossRefPubMed
  304. 304
    ↵
    AldigierJCKanjanbuchTMaLJBrownNJFogoAB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005;16:3306–3314.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  305. 305
    ↵
    VealeDPepinJLLevyPA. Autonomic stress tests in obstructive sleep apnea and snoring. Sleep 1992;15:505–513.
    Google ScholarPubMedWeb of Science
  306. 306
    ↵
    ZoccaliCMallamaciFTripepiGBenedettoFA. Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodeling in dialysis patients. Nephrol Dial Transplant 2001;16:70–77.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  307. 307
    ↵
    QuercioliAMachFMontecuccoF. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath 2010;14:261–269.
    Google ScholarCrossRefPubMed
  308. 308
    MinoguchiKYokoeTTazakiTMinoguchiHTanakaAOdaNOkadaSOhtaSNaitoHAdachiM. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:625–630.
    Google ScholarCrossRefPubMedWeb of Science
  309. 309
    ↵
    GarveyJFTaylorCTMcNicholasWT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009;33:1195–1205.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  310. 310
    ↵
    DempseyJAVeaseySCMorganBJO’DonnellCP. Pathophysiology of sleep apnea. Physiol Rev 2010;90:47–112.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  311. 311
    ↵
    SomersVKWhiteDPAminRAbrahamWTCostaFCulebrasADanielsSFlorasJSHuntCEOlsonLJPickeringTGRussellRWooMYoungT. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 2008;52:686–717.
    Google ScholarCrossRefPubMedWeb of Science
  312. 312
    MarinJMCarrizoSJVicenteEAgustiAG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046–1053.
    Google ScholarCrossRefPubMedWeb of Science
  313. 313
    YaggiHKConcatoJKermanWNLichtmanJHBrassLMMohseninV. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034–2041.
    Google ScholarCrossRefPubMedWeb of Science
  314. 314
    MasudaTMurataMHonmaSIwazuYSasakiNOguraMOnishiAAndoYMutoSShimadaKKarioKKusanoEAsanoY. Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients. Nephrol Dial Transplant 2011;26:2289–2295.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  315. 315
    TangSCLamBYaoTJLeungWSChuCMHoYWIpMSLaiKN. Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis. Kidney Int 2010;77:1031–1038.
    Google ScholarCrossRefPubMedWeb of Science
  316. 316
    ↵
    JungHHLeeJHBaekHJKimSJLeeJJ. Nocturnal hypoxemia and periodic limb movement predict mortality in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2010;5:1607–1613.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  317. 317
    ↵
    LattimoreJLWilcoxISkiltonMLangenfeldMCelermajerDS. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 2006;61:491–495.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  318. 318
    El SolhAAAkinnusiMEBaddouraFHMankowskiCR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007;175:1186–1191.
    Google ScholarCrossRefPubMedWeb of Science
  319. 319
    SchulzRMahmoudiSHattarKSibeliusUOlschewskiHMayerKSeegerWGrimmingerF. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162:566–570.
    Google ScholarCrossRefPubMedWeb of Science
  320. 320
    YokoeTMinoguchiKMatsuoHOdaNMinoguchiHYoshinoGHiranoTAdachiM. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129–1134.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  321. 321
    SchulzRSchmidtDBlumALopes-RibeiroXLückeCMayerKOlschewskiHSeegerWGrimmingerF. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 2000;55:1046–1051.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  322. 322
    ↵
    PhillipsBGNarkiewiczKPesekCAHaynesWGDykenMESomersVK. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999;17:61–66.
    Google ScholarCrossRefPubMedWeb of Science
  323. 323
    ↵
    BeguinPCBelaidiEGodin-RibuotDLevyPRibuotC. Intermittent hypoxia-induced delayed cardioprotection is mediated by PKC and triggered by p38 MAP kinase and Erk1/2. J Mol Cell Cardiol 2007;42:343–351.
    Google ScholarCrossRefPubMedWeb of Science
  324. 324
    MinetEArnouldTMichelGRolandIMottetDRaesMRemacleJMichielsC. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000;468:53–58.
    Google ScholarCrossRefPubMedWeb of Science
  325. 325
    ↵
    ZouAPYangZZLiPLCowleyAWJr Oxygen-dependent expression of hypoxia-inducible factor-1 alpha in renal medullary cells of rats. Physiol Genomics. 2001;6:159–168.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  326. 326
    ↵
    MiraliakbariRFrancalanciaNALustRMGerardoJANgPCSunYSChitwoodWRJr Differences in myocardial and peripheral VEGF and KDR levels after acute ischemia. Ann Thorac Surg 2000;69:1750–1753.
    Google ScholarCrossRefPubMedWeb of Science
  327. 327
    ↵
    KanekoTShimizuAMiiAFujitaEFujinoTKunugiSDuXAkimotoTTsuruokaSOhashiRMasudaYIinoYKatayamaYFukudaY. Role of matrix metalloproteinase-2 in recovery after tubular damage in acute kidney injury in mice. Nephron Exp Nephrol 2012;122:23–35.
    Google Scholar
  328. 328
    ↵
    LeonardMOKieranNEHowellKBurneMJVaradarajanRDhakshinamoorthySPorterAGO’FarrellyCRabbHTaylorCT. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 2006;20:2624–2626.
    Google ScholarCrossRefAbstract/Full TextPubMed
  329. 329
    SharmaRSharmaMDattaPKSavinVJ. Induction of metallothionein-I protects glomeruli from superoxide-mediated increase in albumin permeability. Exp Biol Med 2002;227:26–31.
    Google ScholarAbstract/Full TextPubMed
  330. 330
    ↵
    YangZZZouAP. Transcriptional regulation of heme oxygenases by HIF-1 alpha in renal medullary interstitial cells. Am J Physiol Renal Physiol 2001;281:F900–F908.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  331. 331
    ↵
    UchidaTRossignolFMatthayMAMounierRCouetteSClottesEClericiC. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 2004;279:14871–14878.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  332. 332
    ↵
    YangZZZhangAYYiFXLiPLZouAP. Redox regulation of HIF-1alpha levels and HO-1 expression in renal medullary interstitial cells. Am J Physiol Renal Physiol 2003;284:F1207–F1215.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  333. 333
    ↵
    ZouAPCowleyAWJr Reactive oxygen species and molecular regulation of renal oxygenation. Acta Physiol Scand 2003;179:233–241.
    Google ScholarCrossRefPubMedWeb of Science
  334. 334
    ↵
    LuTHHsiehSYYenCCWuHCChenKLHungDZChenCHWuCCSuYCChenYWLiuSHHuangCF. Involvement of oxidative stress-mediated ERK1/2 and p38 activation regulated mitochondria-dependent apoptotic signals in methylmercury-induced neuronal cell injury. Toxicol Lett 2011;204:71–80.
    Google ScholarCrossRefPubMed
  335. 335
    ↵
    NangakuMRosenbergerCHeymanSNEckardtKU. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol 2013;40:148–157.
    Google ScholarCrossRefPubMed
  336. 336
    ↵
    OrphanidesCFineLGNormanJT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 1997;52:637–647.
    Google ScholarCrossRefPubMedWeb of Science
  337. 337
    ↵
    NormanJTClarkIMGarciaPL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351–2366.
    Google ScholarCrossRefPubMedWeb of Science
  338. 338
    FalangaVZhouLYufitT. Low oxygen tension stimulates collagen synthesis and COL1A1 transcription through the action of TGF-beta1. J Cell Physiol 2002;191:42–50.
    Google ScholarCrossRefPubMedWeb of Science
  339. 339
    Sanchez-ElsnerTBotellaLMVelascoBCorbiAAttisanoLBernabeuC. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38527–38535.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  340. 340
    Sanchez-ElsnerTBotellaLMVelascoBLangaCBernabeuC. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799–43808.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  341. 341
    Sanchez-ElsnerTRamirezJRSanz-RodriguezFVarelaEBernabeuCBotellaLM. A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SP1 and Smads. J Mol Biol 2004;336:9–24.
    Google ScholarCrossRefPubMedWeb of Science
  342. 342
    SaedGMZhangWCheginiNHolmdahlLDiamondMP. Alteration of type I and III collagen expression in human peritoneal mesothelial cells in response to hypoxia and transforming growth factor-beta 1. Wound Repair Regen 1999;7:504–510.
    Google ScholarCrossRefPubMedWeb of Science
  343. 343
    ↵
    KietzmannTRothUJungermannK. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999;94:4177–4185.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  344. 344
    ↵
    Dore-DuffyPBalabanovRBeaumontTHritzMAHarikSILaMannaJC. Endothelial activation following prolonged hypobaric hypoxia. Microvasc Res 1999;57:75–85.
    Google ScholarCrossRefPubMed
  345. 345
    ↵
    MalaponteGBevelacquaVFatuzzoPRapisardaFEmmanueleGTravaliSMazzarinoMC. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 2002;17:1964–1970.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  346. 346
    ↵
    Sean EardleyKCockwellP. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005;68:437–455.
    Google ScholarCrossRefPubMedWeb of Science
  347. 347
    AlbinaJEHenryWLJrMastrofrancescoBMartinBAReichnerJS. Macrophage activation by culture in an anoxic environment. J Immunol 1995;155:4391–4396.
    Google ScholarAbstractPubMedWeb of Science
  348. 348
    ↵
    LewisJSLeeJAUnderwoodJCHarrisALLewisCE. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 1999;66:889–900.
    Google ScholarAbstractPubMedWeb of Science
  349. 349
    ↵
    LuscinskasFWMaSNusratAParkosCAShawSK. Leukocyte transendothelial migration: a junctional affair. Semin Immunol 2002;14:105–113.
    Google ScholarCrossRefPubMedWeb of Science
  350. 350
    ↵
    KonstantopoulosKHanleyWDWirtzD. Receptor-ligand binding: ‘catch’ bonds finally caught. Curr Biol 2003;13:R611–R613.
    Google ScholarCrossRefPubMedWeb of Science
  351. 351
    ↵
    HayflickJSKilgannonPGallatinWM. The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. Immunol Res 1998;17:313–327.
    Google ScholarCrossRefPubMedWeb of Science
  352. 352
    ↵
    Van der VierenMLe TrongHWoodCLMoorePFSt. JohnTStauntonDEGallatinWM. A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3. Immunity 1995;3:683–690.
    Google ScholarCrossRefPubMedWeb of Science
  353. 353
    ↵
    MazzoneARicevutiG. Leukocyte CD11/CD18 integrins: biological and clinical relevance. Haematologica 1995;80:161–175.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  354. 354
    KingPDBatchelorAHLawlorPKatzDR. The role of CD44, CD45, CD45RO, CD46 and CD55 as potential anti-adhesion molecules involved in the binding of human tonsillar T cells to phorbol 12-myristate 13-acetate-differentiated U-937 cells. Eur J Immunol. 1990;20:363–368.
    Google ScholarCrossRefPubMed
  355. 355
    ↵
    ManjunathNCorreaMArdmanMArdmanB. Negative regulation of T-cell adhesion and activation by CD43. Nature 1995;377:535–538.
    Google ScholarCrossRefPubMed
  356. 356
    ↵
    WoollettGRWilliamsAFShottonDM. Visualisation by low-angle shadowing of the leucocyte-common antigen. A major cell surface glycoprotein of lymphocytes. EMBO J 1985;4:2827–2830.
    Google ScholarPubMed
  357. 357
    ↵
    CysterJGShottonDMWilliamsAF. The dimensions of the T lymphocyte glycoprotein leukosialin and identification of linear protein epitopes that can be modified by glycosylation. EMBO J 1991;10:893–902.
    Google ScholarPubMed
  358. 358
    ↵
    ClarkMCBaumLG. T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci 2012;1253:58–67.
    Google ScholarCrossRefPubMed
  359. 359
    BöhmI. Environment-dependent down-modulation of CD45 cell surface expression on polymorphonuclear cells. J Clin Lab Anal 2004;18:187–194.
    Google ScholarCrossRefPubMed
  360. 360
    ↵
    ShelleyCSBöttingerEPArnaoutMA. Transcriptional regulation of beta 2-integrins. In: GahmbergCGMandrup-PoulsenTWogensen BachLHökfeltB, eds. Leukocyte adhesion: Basic and Clinical Aspects. Amsterdam, The Netherlands: Elsevier Science Publishers;1992. 337–351.
    Google Scholar
  361. 361
    ↵
    Da SilvaNBhartiAShelleyCS. hnRNP-K and Pur alpha act together to repress the transcriptional activity of the CD43 gene promoter. Blood 2002;100:3536–3544.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  362. 362
    ↵
    ShelleyCSDa SilvaNTeodoridisJM. During U937 monocytic differentiation repression of the CD43 gene promoter is mediated by the single-stranded DNA binding protein Purα. Br J Haematol 2001;115:159–166.
    Google ScholarCrossRefPubMedWeb of Science
  363. 363
    ↵
    BazilVStromingerJL. CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes. Proc Natl Acad Sci USA 1993;90:3792–3796.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  364. 364
    ↵
    StewartMHoggN. Regulation of leukocyte integrin function: affinity vs. avidity. J Cell Biochem 1996;61:554–561.
    Google ScholarCrossRefPubMedWeb of Science
  365. 365
    ↵
    SpringerTAAndersonDC. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis, and migration into inflammatory sites: insights from an experiment of nature. Ciba Found Symp 1986;118:102–126.
    Google ScholarPubMed
  366. 366
    ↵
    ShelleyCSFarokhzadOCArnaoutMA. Identification of cell-specific and developmentally-regulated nuclear factors which direct myeloid and lymphoid expression of the CD11a gene. Proc Natl Acad Sci USA 1993;90:5364–5368.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  367. 367
    ShelleyCSArnaoutMA. The promoter of the CD11b gene directs myeloid specific and developmentally-regulated expression. Proc Natl Acad Sci USA 1991;88:10525–10529.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  368. 368
    ↵
    ShelleyCSTeodoridisJMParkHFarokhzadOCBöttingerEPArnaoutMA. During differentiation of the monocytic cell line U937, Pur alpha mediates induction of the CD11c gene promoter. J Immunol 2002;168:3887–3893.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  369. 369
    ↵
    BöttingerEPShelleyCSFarokhzadOCArnaoutMA. The human beta2 integrin CD18 promoter consists of two inverted Ets cis elements. Mol Cell Biol 1994;14:2604–2615.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  370. 370
    ↵
    FarokhzadOCShelleyCSBöttingerEPArnaoutMA. Induction of the CD11b gene during myeloid differentiation requires its interaction with the novel transcription factor MS-2. J Immunol 1996;157:5597–5605.
    Google ScholarAbstract/Full TextPubMedWeb of Science
  371. 371
    ↵
    NicolaouFTeodoridisJMParkHGeorgakisAFarokhzadOCBöttingerEPDa SilvaNRousselotPChomienneCFerencziKArnaoutMAShelleyCS. CD11c gene expression in hairy-cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. Blood 2003;101:4033–4041.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  372. 372
    ↵
    CampbellELBruyninckxWJKellyCJGloverLEMcNameeENBowersBEBaylessAJScullyMSaeediBJGolden-MasonLEhrentrautSFCurtisVFBurgessAGarveyJFSorensenANemenoffRJedlickaPTaylorCTKominskyDJColganSP. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 2014;40:66–77.
    Google ScholarCrossRefPubMedWeb of Science
  373. 373
    ↵
    de DiosIRamudoLGarcia-MonteroACMansoMA. Redox-senstitive modulation of CD45 expression in pancreatic acinar cells during acute pancreatitis. J Pathol 2006;210:234–239.
    Google ScholarCrossRefPubMed
  374. 374
    ↵
    Remold-O’DonnellEParentD. Downregulation of neutrophil CD43 by opsonized zymosan. Blood 1995;85:337–342.
    Google ScholarAbstract/Full TextPubMed
  375. 375
    ↵
    HochmanMEWattJPReidRO’BrienKL. The prevalence and incidence of end-stage renal disease in Native American adults on the Navajo reservation. Kidney Int 2007;71:931–937.
    Google ScholarCrossRefPubMedWeb of Science
  376. 376
    ↵
    ChenWLiuQWangHChenWJohnsonRJDongXLiHBaSTanJLuoNLiuTHeHYuX. Prevalence and risk factors of chronic kidney disease: a population study in the Tibetan population. Nephrol Dial Transplant 2011;26:1592–1599.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  377. 377
    ↵
    MasudaTHonmaSSasakiNHanawa-YazawaSIwazuYKusanoEAsanoY. Effect of continuous positive airway pressure on proteinuria in obstructive sleep apnea. Clin Kidney J 2012;5:257–260.
    Google ScholarCrossRefAbstract/Full TextPubMed
  378. 378
    ↵
    AnJDevaneyBOoiKYFordSFrawleyGMenahemS. Hyperbaric oxygen in the treatment of calciphylaxis: a case series and literature review. Nephrology (Carlton) 2015;20:444–450.
    Google ScholarCrossRefPubMed
  379. 379
    ↵
    IshikawaMKobayashiNSugiyamaFOnodaSIshimitsuT. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Int Heart J 2013;54:98–106.
    Google ScholarCrossRefPubMed
  380. 380
    ↵
    RenkeMLizakowskiSTylickiLRutkowskiPKnapNHeleniakZSławińska-MorawskaMAleksandrowicz-WronaEJanuszczykJWójcik-StasiakMMałgorzewiczSWoźniakMRutkowskiB. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study. Adv Med Sci 2014;59:256–260.
    Google ScholarCrossRefPubMed
  381. 381
    ↵
    JuncosLICaputoJ. Combination therapy in chronic kidney disease? Ther Adv Cardiovasc Dis 2015;9:147–152.
    Google ScholarCrossRefAbstractPubMed
  382. 382
    ↵
    HayashiKHommaKWakinoSTokuyamaHSuganoNSarutaTItohH. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010;59:84–95.
    Google ScholarCrossRefPubMed
  383. 383
    ↵
    AndressDLCollBPritchettYBrennanJMolitchMKohanDE. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD) Life Sci 2012;91:739–742.
    Google ScholarCrossRefPubMed
  384. 384
    ↵
    GassanovNNiaAMCaglayanEErF. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J Am Soc Nephrol 2014;25:216–224.
    Google ScholarCrossRefAbstract/Full TextPubMed
  385. 385
    ↵
    Mahfoudh-BoussaidAZaoualiMAHadj-AyedKMiledAHSaidane-MosbahiDRosello-CatafauJBen AbdennebiH. Ischemic preconditioning reduces endoplasmic reticulum stress and upregulates hypoxia inducible factor-1α in ischemic kidney: the role of nitric oxide. J Biomed Sci 2012;19:7.
    Google ScholarCrossRefPubMed
  386. 386
    ↵
    MaDLimTXuJTangHWanYZhaoHHossainMMaxwellPHMazeM. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009;20:713–720.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  387. 387
    ZhangLHuangHChengJLiuJZhaoHVizcaychipiMPMaD. Pre-treatment with isoflurane ameliorates renal ischemic-reperfusion injury in mice. Life Sci 2011;88:1102–1107.
    Google ScholarCrossRefPubMedWeb of Science
  388. 388
    BernhardtWMCâmpeanVKanySJürgensenJSWeidemannAWarneckeCArendMKlausSGünzlerVAmannKWillamCWiesenerMSEckardtKU. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 2006;17:1970–1978.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  389. 389
    WeidemannABernhardtWMKlankeBDanielCBuchholzBCâmpeanVAmannKWarneckeCWiesenerMSEckardtKUWillamC. HIF activation protects from acute kidney injury. J Am Soc Nephrol 2008;19:486–494.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  390. 390
    ↵
    MatsumotoMMakinoYTanakaTTanakaHIshizakaNNoiriEFujitaTNangakuM. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 2003;14:1825–1832.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  391. 391
    ↵
    KaelinWGJrRatcliffePJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393–402.
    Google ScholarCrossRefPubMedWeb of Science
  392. 392
    ↵
    MoleDRSchlemmingerIMcNeillLAHewitsonKSPughCWRatcliffePJSchofieldCJ. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett 2003;13:2677–2680.
    Google ScholarCrossRefPubMed
  393. 393
    ↵
    EpsteinACGleadleJMMcNeillLAHewitsonKSO’RourkeJMoleDRMukherjiMMetzenEWilsonMIDhandaATianYMMassonNHamiltonDLJaakkolaPBarsteadRHodgkinJMaxwellPHPughCWSchofieldCJRatcliffePJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43–54.
    Google ScholarCrossRefPubMedWeb of Science
  394. 394
    ↵
    HirsiläMKoivunenPGünzlerVKivirikkoKIMyllyharjuJ. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003; 278:30772–30780.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  395. 395
    ↵
    SchlemmingerIMoleDRMcNeillLADhandaAHewitsonKSTianYMRatcliffePJPughCWSchofieldCJ. Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases. Bioorg Med Chem Lett 2003;13:1451–1454.
    Google ScholarCrossRefPubMed
  396. 396
    ↵
    FlightMH. Deal watch: AstraZeneca bets on FibroGen’s anaemia drug. Nat Rev Drug Discov 2013;12:730
    Google ScholarCrossRefPubMed
  397. 397
    ↵
    CohenDLTownsendRR. Is there added value to adding ARB to ACE inhibitors in the management of CKD? J Am Soc Nephrol 2009;20:1666–1668.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  398. 398
    ↵
    TylickiLRutkowskiPRenkeMLarczyńskiWAleksandrowiczELysiak-SzydlowskaWRutkowskiB. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008;52:486–493.
    Google ScholarCrossRefPubMedWeb of Science
  399. 399
    ↵
    AyoubMAZhangYKellyRSSeeHBJohnstoneEKMcCallEAWilliamsJHKellyDJPflegerKD. Fuctional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease. PLoS One 2015;10:e0119803.
    Google ScholarCrossRefPubMed
  400. 400
    ↵
    LeonardECFriedrichJLBasileDP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol 2008;295:F1648–F1657.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  401. 401
    ↵
    JungYJKimDHLeeASLeeSKangKPLeeSYJangKYSungMJParkSKKimW. Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury. Am J Physiol Renal Physiol 2009;297:F952–F960.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  402. 402
    ↵
    LongJWangYWangWChangBHDaneshFR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010;285:23457–23465.
    Google ScholarCrossRefAbstract/Full TextPubMed
  403. 403
    ↵
    EirinAEbrahimiBZhangXZhuXYWoollardJRHeQTextorSCLermanALermanLO. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res 2014;103:461–471.
    Google ScholarCrossRefAbstract/Full TextPubMed
  404. 404
    ↵
    ChenJFLiuHNiHFLvLLZhangMHZhangAHTangRNChenPSLiuBC. Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats. PLoS One 2013;8:e83593.
    Google ScholarCrossRefPubMed
  405. 405
    ↵
    YangYWangJQinLShouZZhaoJWangHChenYChenJ. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007;27:495–502.
    Google ScholarCrossRefPubMedWeb of Science
  406. 406
    ↵
    ChadeARRodriguez-PorcelMHerrmannJZhuXGrandeJPNapoliCLermanALermanLO. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004;15:958–966.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  407. 407
    ↵
    VaziriNDLiuSFarzanehSHNazertehraniSKhazaeliMZhaoYY. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease. Free Radic Biol Med 2015;86:374–381.
    Google ScholarCrossRefPubMed
  408. 408
    ↵
    FriederichMFaschingAHansellPNordquistLPalmF. Diabetes-induced up-regulation of uncoupling protein-2 results in increased mitochondrial uncoupling in kidney proximal tubular cells. Biochim Biophys Acta 2008;1777:935–940.
    Google ScholarPubMedWeb of Science
  409. 409
    ↵
    ElmarakbyAAFaulknerJBabanBSalehMASullivanJC. Induction of hemeoxygenase-1 reduces glomerular injury and apoptosis in diabetic spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2012;302:F791–F800.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  410. 410
    ↵
    WongMSaadSZhangJGrossSJarolimekWSchilterHChenJAGillAJPollockCAWongMG. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. Am J Physiol Renal Physiol 2014;307:F908–F916.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  411. 411
    ↵
    LeeJHKimJHKimJSChangJWKimSBParkJSLeeSK. AMP-activated protein kinase inhibits TGF-β-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol 2013;304:F686–F697.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  412. 412
    ↵
    MoningkaNCTsarovaTSasserJMBaylisC. Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. Nephrol Dial Transplant 2012;27:913–920.
    Google ScholarCrossRefAbstract/Full TextPubMed
  413. 413
    ↵
    RenkeMTylickiLRutkowskiPKnapNZietkiewiczMNeuweltAAleksandrowiczEŁysiak-SzydłowskaWWoźniakMRutkowskiB. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim Pol 2010;57:119–123.
    Google ScholarPubMed
  414. 414
    ↵
    ElmarakbyAAFaulknerJPyeCRouchKAlhashimAMaddipatiKRBabanB. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats. Clin Sci 2013;125:349–359.
    Google ScholarCrossRefPubMed
  415. 415
    ↵
    DuPontJJRamickMGFarquharWBTownsendRREdwardsDG. NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease. Am J Physiol Renal Physiol 2014;306:F1499–F1506.
    Google ScholarCrossRefAbstract/Full TextPubMed
  416. 416
    ↵
    BayomiHSElsherbinyNMEl-GayarAMAl-GayyarMM. Evaluation of renal protective effects of inhibiting TGF-β type I receptor in a cisplatin-induced nephrotoxicity model. Eur Cytokine Netw 2013;24:139–147.
    Google ScholarPubMed
  417. 417
    ↵
    SankaranDBankovic-CalicNOgbornMRCrowGAukemaHM. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 2007;293:F821–F830.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  418. 418
    ↵
    VillanuevaSCarreñoJESalazarLVergaraCStrodthoffRFajreFCéspedesCSáezPJIrarrázabalCBartolucciJFigueroaFVioCP. Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure. Clin Sci 2013;125:199–210.
    Google ScholarCrossRefPubMed
  419. 419
    ↵
    AroorAMcKarnsSNistalaRDemarcoVGardnerMGarcia-TouzaMWhaley-ConnellASowersJR. DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med 2013;3:48–56.
    Google ScholarCrossRefPubMed
  420. 420
    ↵
    ImpellizzeriDEspositoEAttleyJCuzzocreaS. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res 2014;81:91–102.
    Google ScholarCrossRefPubMed
  421. 421
    ↵
    DuffieldJSHongSVaidyaVSLuYFredmanGSerhanCNBonventreJV. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 2006;177:5902–5911.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  422. 422
    ↵
    PengAGuYLinSY. Herbal treatment for renal diseases. Ann Acad Med Singapore 2005;34:44–51.
    Google ScholarPubMed
  423. 423
    ↵
    NgYYHouCCWangWHuangXRLanHY. Blockade of NFkB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl 2005;94:S83–S91.
    Google ScholarPubMed
  424. 424
    ↵
    AndersHJNinichukVSchlöndorffD. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 2006;69:29–32.
    Google ScholarCrossRefPubMedWeb of Science
  425. 425
    ↵
    SeokSJLeeESKimGTHyunMLeeJHChenSChoiRKimHMLeeEYChungCH. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol Dial Transplant 2013;28:1700–1710.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  426. 426
    ↵
    HuartAKleinJGonzalezJBuffin-MeyerBNeauEDelageCCaliseDRibesDSchanstraJPBascandsJL. Kinin B1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive. Front Pharmacol 2015;6:8.
    Google ScholarPubMed
  427. 427
    ↵
    LiuHZhangXPYiZW. Efficacy of antisense monocyte chemoattractant protein-1 (MCP-1) in a rat model of mesangial proliferative glomerulonephritis. Ren Fail 2013;35:1418–1428.
    Google ScholarCrossRefPubMed
  428. 428
    ↵
    RemuzziGPericoNMaciaMRuggenentiP. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005;99:S57–S65.
    Google ScholarPubMed
  429. 429
    ↵
    DaiYZhangWWenJZhangYKellemsREXiaY. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. J Am Soc Nephrol 2011;22:890–901.
    Google ScholarCrossRefAbstract/Full TextPubMed
  430. 430
    ↵
    FalkeLLGoldschmedingRNguyenTQ. A perspective on anti-CCN2 therapy for chronic kidney disease. Nephrol Dial Transplant 2014;29 Suppl 1:i30–i37.
    Google ScholarCrossRefAbstract/Full TextPubMed
  431. 431
    ↵
    LiuNGuoJKPangMTolbertEPonnusamyMGongRBaylissGDworkinLDYanHZhuangS. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol 2012;23:854–867.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  432. 432
    ↵
    BoorPKoniecznyAVillaLKunterUvan RoeyenCRLaRochelleWJSmithsonGArrolSOstendorfTFloegeJ. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 2007;22:1323–1331.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  433. 433
    ↵
    HaoSHeWLiYDingHHouYNieJHouFFKahnMLiuY. Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011;22:1642–1653.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  434. 434
    ↵
    KellyDJEdgleyAJZhangYThaiKTanSMCoxAJAdvaniAConnellyKAWhitesideCIGilbertRE. Protein kinase C-β inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrol Dial Transplant 2009;24:1782–1790.
    Google ScholarCrossRefAbstract/Full TextPubMed
  435. 435
    ↵
    HuangCPollockCAChenXM. KCa3.1: a new player in progressive kidney disease. Curr Opin Nephrol Hypertens 2015;24:61–66.
    Google ScholarCrossRefPubMed
  436. 436
    ↵
    ChenLHAdvaniSLThaiKKabirMGSoodMMGibsonIWYuenDAConnellyKAMarsdenPAKellyDJGilbertREAdvaniA. SDF-1/CXCR4 signaling preserves microvascular integrity and renal function in chronic kidney disease. PLoS One 2014;9:e92227.
    Google ScholarCrossRefPubMed
  437. 437
    ↵
    IekushiKTaniyamaYAzumaJSanadaFKusunokiHYokoiTKoibuchiNOkayamaKRakugiHMorishitaR. Hepatocyte growth factor attenuates renal fibrosis through TGF-β1 suppression by apoptosis of myofibroblasts. J Hypertens 2010;28:2454–2461.
    Google ScholarPubMedWeb of Science
  438. 438
    ↵
    PetrovaDTBrandhorstGBrehmerFGrossOOellerichMArmstrongVW. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. Ther Drug Monit 2010;32:405–412.
    Google ScholarCrossRefPubMedWeb of Science
  439. 439
    ↵
    ZeisbergMKalluriR. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008;23:1395–1398.
    Google ScholarCrossRefPubMed
  440. 440
    ↵
    SomaJSugawaraTHuangYDNakajimaJKawamuraM. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002;92:693–698.
    Google ScholarCrossRefPubMedWeb of Science
  441. 441
    ↵
    LiuCMeiWTangJYuanQHuangLLuMWuLPengZMengJYangHShenHLvBHuGTaoL. Mefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstruction. PLoS One 2015;10:e0129283.
    Google ScholarCrossRefPubMed
  442. 442
    ↵
    BieleszBSirinYSiHNiranjanTGruenwaldAAhnSKatoHPullmanJGesslerMHaaseVHSusztakK. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010;120:4040–4054.
    Google ScholarCrossRefPubMedWeb of Science
  443. 443
    ↵
    OlzinskiARMcCaffertyTAZhaoSQBehmDJEybyeMEManiscalcoKBentleyRFrazierKSMillinerCMMirabileRCCoatneyRWWilletteRN. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc Res 2005;66:170–178.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  444. 444
    ↵
    JinYRatnamKChuangPYFanYZhongYDaiYMazloomARChenEYD’AgatiVXiongHRossMJChenNMa’ayanAHeJC. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 2012;18:580–588.
    Google ScholarCrossRefPubMed
  445. 445
    ↵
    HayakawaSOhashiKShibataRKataokaYMiyabeMEnomotoTJokiYShimizuYKambaraTUemuraYYuasaDOgawaHMatsuoKHiramatsu-ItoMvan den HoffMJWalshKMuroharaTOuchiN. Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal nephrectomy model. J Am Soc Nephrol 2015;26:636–646.
    Google ScholarCrossRefAbstract/Full TextPubMed
  446. 446
    ↵
    DellêHRochaJRCavaglieriRCVieiraJMJrMalheirosDMNoronhaIL. Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol 2012;23:37–48.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  447. 447
    ↵
    SaglamFCelikATayfurDCavdarZYilmazOSariogluSKolatanEOktayGCamsariT. Decrease in cell proliferation by an matrix metalloproteinase inhibitor, doxycycline, in a model of immune-complex nephritis. Nephrology 2010;15:560–567.
    Google ScholarCrossRefPubMed
  448. 448
    ↵
    KapitsinouPPJaffeJMichaelMSwanCEDuffyKJErickson-MillerCLHaaseVH. Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol 2012;302:F1172–F1179.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
  449. 449
    ↵
    SchleyGKlankeBSchödelJForstreuterFShuklaDKurtzAAmannKWiesenerMSRosenSEckardtKUMaxwellPHWillamC. Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J Am Soc Nephrol 2011;22:2004–2015.
    Google ScholarCrossRefAbstract/Full TextPubMedWeb of Science
Loading
Back to top
In this Issue
Clinical Medicine & Research
Clinical Medicine & Research

Vol. 14, Issue 1

1 Mar 2016

Table of Contents Cover (Photo) Index by author
  • Print
  • Download PDF
  • Article Alerts

    Alerts for this Article

    Sign In to Email Alerts with your Email Address
  • Email Article

    Email This Article

  • Citation Tools

    Citation Tools

    Hypoxia: The Force that Drives Chronic Kidney Disease
    • Clinical Medicine & Research
    • Mar 2016 ,
    • 14
    • (1)
    • 15-
    • 39;
    • DOI: 10.3121/cmr.2015.1282

    Citation Manager Formats

  • Share

    Share This Article

    Hypoxia: The Force that Drives Chronic Kidney Disease
    • Clinical Medicine & Research
    • Mar 2016 ,
    • 14
    • (1)
    • 15-
    • 39;
    • DOI: 10.3121/cmr.2015.1282
  • Bookmark this Article

    SAVE ITEM IN SELECTED FOLDER.

Jump to

Keywords

Hypoxia, Kidney disease, Leukocyte adhesion, CD43, CD45, β2-integrins, Gene transcription